<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523416308042</prism:url><dc:identifier>doi:10.1016/j.ejmech.2016.09.068</dc:identifier><eid>1-s2.0-S0223523416308042</eid><prism:doi>10.1016/j.ejmech.2016.09.068</prism:doi><pii>S0223-5234(16)30804-2</pii><dc:title>Antagonizing STAT3 activation with benzo[b]thiophene 1, 1-dioxide based small molecules </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>125</prism:volume><prism:startingPage>538</prism:startingpage><prism:endingPage>550</prism:endingpage><prism:pageRange>538-550</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2017-01-05</prism:coverdate><prism:coverDisplayDate>5 January 2017</prism:coverdisplaydate><prism:copyright>© 2016 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Zhang, Wenda</dc:creator><dc:creator>Ma, Ting</dc:creator><dc:creator>Li, Shanshan</dc:creator><dc:creator>Yang, Yanwei</dc:creator><dc:creator>Guo, Jianpeng</dc:creator><dc:creator>Yu, Wenying</dc:creator><dc:creator>Kong, Lingyi</dc:creator><dc:description>
                  STAT3 is an attractive therapeutic target for cancer therapy. However, due to low potency or poor druggability, none of its inhibitors are clinically available. Herein, a series of aminobenzo[b]thiophene 1, 1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors. Most of them exhibited higher antitumor activity than the small-molecule STAT3 inhibitor, Stattic. Compound 15 was the most potent and had an IC50 range in 0.33–0.75 μM in various cancer cell lines. The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by 15 without influencing the phosphorylation levels of the upstream kinases Src and Jak2. 15 also suppressed the expressions of STAT3 downstream gene, Bcl-2. 15 effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk. Furthermore, 15 
                     in vivo induced significant antitumor responses, and exhibited less toxicity than Doxorubicin. Together, this study described a class of new STAT3 inhibitors as antitumor agents.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Antitumor agents</dcterms:subject><dcterms:subject>Aminobenzo[b]thiophene 1, 1-dioxides</dcterms:subject><dcterms:subject>Drug-likeness properties</dcterms:subject><dcterms:subject>STAT3 phosphorylation, Apoptosis</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523416308042" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523416308042" rel="scidir"/></link></coredata><objects><object ref="gr7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="113" size="16556">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr7.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="157" size="14702">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="172" height="163" size="31502">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="165" height="163" size="19680">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="57" size="6883">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="gr10" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="16794">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr10.sml?httpAccept=%2A%2F%2A</object><object ref="gr11" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="192" height="164" size="16407">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr11.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="142" size="26168">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="92" size="13827">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr9.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="66" size="12198">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="72" size="16842">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="19115">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="146" size="23661">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="101" size="14597">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr8.sml?httpAccept=%2A%2F%2A</object><object ref="gr7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="195" size="34745">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr7.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="398" size="70390">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="614" size="174288">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="535" height="530" size="76371">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="373" height="98" size="20735">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr10" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="256" size="51741">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr10.jpg?httpAccept=%2A%2F%2A</object><object ref="gr11" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="476" size="64745">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr11.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="362" size="81278">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="580" height="245" size="53507">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr9.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="151" size="40474">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="182" size="51830">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="557" height="313" size="64709">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="253" size="46769">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="646" height="297" size="73671">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-gr8.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Microsoft Word file" mimetype="application/word" size="58098192">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523416308042-mmc1.docx?httpAccept=%2A%2F%2A</object></objects><scopus-id>84989951485</scopus-id><scopus-eid>2-s2.0-84989951485</scopus-eid><pubmed-id>27718470</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84989951485" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20160922">2016-09-22</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20160922">2016-09-22</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20161102">2016-11-02</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20161102">2016-11-02</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2016-12-05T10:19:59</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523416308042</xocs:eid>
      <xocs:pii-formatted>S0223-5234(16)30804-2</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523416308042</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2016.09.068</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523416X00177</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20161205">2016-12-05T05:37:41.498314-05:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20170105</xocs:date-search-begin>
      <xocs:year-nav>2017</xocs:year-nav>
      <xocs:indexeddate epoch="1474557674">2016-09-22T15:21:14.06913Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast grantnumber grantsponsor grantsponsorid highlightsabst orcid otherkwds primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>125</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>125</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 125</xocs:vol-iss-suppl-text>
      <xocs:sort-order>42</xocs:sort-order>
      <xocs:first-fp>538</xocs:first-fp>
      <xocs:last-lp>550</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>538</xocs:first-page>
         <xocs:last-page>550</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20170105</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>5 January 2017</xocs:cover-date-text>
      <xocs:cover-date-start>2017-01-05</xocs:cover-date-start>
      <xocs:cover-date-year>2017</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>© 2016 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>ANTAGONIZINGSTAT3ACTIVATIONBENZOBTHIOPHENE11DIOXIDEBASEDSMALLMOLECULES</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>ZHANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>W</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biological evaluation</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>In vitro cell growth inhibitory activity</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular docking</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>compound <ce:bold>15</ce:bold> inhibited STAT3 activity in tumor cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> inhibited STAT3 phosphorylation induced by interleukin-6 (IL-6)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> inhibited STAT3 DNA-binding activity</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Typical upstream or other kinases of STAT3 were not inhibited by <ce:bold>15</ce:bold>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> inhibited the expression of the downstream gene of STAT3, Bcl-2, and induced the apoptosis of cancer cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> induced the ROS generation in tumor cells</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> inhibited tumor cells colony formation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>2.3.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Compound <ce:bold>15</ce:bold> exhibited antitumor activity <ce:italic>in vivo</ce:italic>
                  </xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Materials and methods</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of <ce:bold>2a</ce:bold> and <ce:bold>2b</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Methyl 6-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylate (<ce:bold>2a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.1.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>Methyl 7-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylate (<ce:bold>2b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of <ce:bold>3a</ce:bold> and <ce:bold>3b</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylic acid (<ce:bold>3a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.2.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylic acid (<ce:bold>3b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of <ce:bold>4a</ce:bold> and <ce:bold>4b</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-bromobenzo[b] thiophene (<ce:bold>4a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.3.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-bromobenzo[b] thiophene (<ce:bold>4b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of <ce:bold>5a</ce:bold> and <ce:bold>5b</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-bromobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>5a</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.4.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-bromobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>5b</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>General procedures for the preparation of <ce:bold>6</ce:bold>–<ce:bold>29</ce:bold>
                  </xocs:item-toc-section-title>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.1</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((3-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>6</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.2</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((4-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>7</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.3</xocs:item-toc-label>
                     <xocs:item-toc-section-title>3-((1, 1-dioxidobenzo[<ce:italic>b</ce:italic>]thiophen-6-yl) amino) benzonitrile (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.4</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((4-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.5</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((4-chlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>10</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.6</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((3, 4-dichlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>11</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.7</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((3, 4-difluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.8</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 4, 5-trimethoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.9</xocs:item-toc-label>
                     <xocs:item-toc-section-title>6-((3-(trifluoromethoxy) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>14</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.10</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>15</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.11</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((4-(trifluoromethoxy) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>16</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.12</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 4, 5-trimethoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>17</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.13</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((4-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>18</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.14</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((4-chlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>19</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.15</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 5-dimethylphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>20</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.16</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((Perfluorophenyl) amino)benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>21</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.17</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3-Fluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>22</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.18</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-(p-tolylamino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>23</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.19</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((4-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>24</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.20</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((2-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>25</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.21</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 4-difluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>26</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.22</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 4-dichlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>27</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.23</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((3, 5-bis (trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>28</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
                  <xocs:item-toc-entry ref-elem="ce:sections">
                     <xocs:item-toc-label>4.1.5.24</xocs:item-toc-label>
                     <xocs:item-toc-section-title>7-((2-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>29</ce:bold>)</xocs:item-toc-section-title>
                  </xocs:item-toc-entry>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Docking</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Maintenance of cell lines culture and cell viability assays</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>IL-6 induction of STAT3 phosphorylation</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>Electrophoretic mobility shift assay (EMSA) of DNA-binding activity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>Flow cytometry analysis of apoptotic cells</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>ROS detection by flow cytometry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>Colony survival assay</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>In vivo studies</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1630</xocs:ref-first-fp>
            <xocs:ref-last-lp>1635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>HAFTCHENARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>115</xocs:ref-first-fp>
            <xocs:ref-last-lp>127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1159</xocs:ref-first-fp>
            <xocs:ref-last-lp>1168</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>4402</xocs:ref-first-fp>
            <xocs:ref-last-lp>4412</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>ESCOBAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4551</xocs:ref-first-fp>
            <xocs:ref-last-lp>4562</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>LAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6549</xocs:ref-first-fp>
            <xocs:ref-last-lp>6558</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>HAFTCHENARY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>115</xocs:ref-first-fp>
            <xocs:ref-last-lp>127</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2468</xocs:ref-first-fp>
            <xocs:ref-last-lp>2473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>825</xocs:ref-first-fp>
            <xocs:ref-last-lp>833</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>7190</xocs:ref-first-fp>
            <xocs:ref-last-lp>7200</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>FLETCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1459</xocs:ref-first-fp>
            <xocs:ref-last-lp>1470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7391</xocs:ref-first-fp>
            <xocs:ref-last-lp>7396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>787</xocs:ref-first-fp>
            <xocs:ref-last-lp>798</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>JING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>279</xocs:ref-first-fp>
            <xocs:ref-last-lp>286</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>WEERASINGHE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>136</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1459</xocs:ref-first-fp>
            <xocs:ref-last-lp>1469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>LIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>39</xocs:ref-first-fp>
            <xocs:ref-last-lp>50</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>BALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>e18820</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>SHIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>193</xocs:ref-first-fp>
            <xocs:ref-last-lp>202</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>180</xocs:ref-first-fp>
            <xocs:ref-last-lp>185</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>195</xocs:ref-first-fp>
            <xocs:ref-last-lp>203</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9623</xocs:ref-first-fp>
            <xocs:ref-last-lp>9628</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>HUANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>783</xocs:ref-first-fp>
            <xocs:ref-last-lp>792</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>TIMOFEEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>799</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>KOTHA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>621</xocs:ref-first-fp>
            <xocs:ref-last-lp>629</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>NATARAJAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>6506</xocs:ref-first-fp>
            <xocs:ref-last-lp>6513</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>BHARTI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3863</xocs:ref-first-fp>
            <xocs:ref-last-lp>3871</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>SATURNINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>112</xocs:ref-first-fp>
            <xocs:ref-last-lp>119</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>PALLANDRE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>163</xocs:ref-first-fp>
            <xocs:ref-last-lp>174</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>JI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>1010</xocs:ref-first-fp>
            <xocs:ref-last-lp>1014</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>51</xocs:ref-first-fp>
            <xocs:ref-last-lp>62</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>ZHANGX2017X538</xocs:refkey3>
         <xocs:refkey4lp>ZHANGX2017X538X550</xocs:refkey4lp>
         <xocs:refkey4ai>ZHANGX2017X538XW</xocs:refkey4ai>
         <xocs:refkey5>ZHANGX2017X538X550XW</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:self-archiving>
         <xocs:sa-start-date>2018-11-02T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-embargo-status>UnderEmbargo</xocs:sa-embargo-status>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2016 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(16)30804-2</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523416308042</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523416308042</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2016.09.068</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2016-12-05T05:37:41.498314-05:00</xocs:timestamp>
         <xocs:cover-date-start>2017-01-05</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/MAIN/application/pdf/9a7fa294c9322d739d7041bf52c10609/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/MAIN/application/pdf/9a7fa294c9322d739d7041bf52c10609/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>2672567</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>13</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523416308042-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/PREVIEW/image/png/2b6b547444d63a62a46fbe2ef7012654/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/PREVIEW/image/png/2b6b547444d63a62a46fbe2ef7012654/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>57043</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr7/THUMBNAIL/image/gif/11f091105ee5d9451be9abe166c149a2/gr7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr7/THUMBNAIL/image/gif/11f091105ee5d9451be9abe166c149a2/gr7.sml</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16556</xocs:filesize>
               <xocs:pixel-height>113</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/sc1/THUMBNAIL/image/gif/59da2b9661f2d9cd97347eddfccd68aa/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/sc1/THUMBNAIL/image/gif/59da2b9661f2d9cd97347eddfccd68aa/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14702</xocs:filesize>
               <xocs:pixel-height>157</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr3/THUMBNAIL/image/gif/5dc2368755cca11ea9be60fe95fb140c/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr3/THUMBNAIL/image/gif/5dc2368755cca11ea9be60fe95fb140c/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>31502</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>172</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr5/THUMBNAIL/image/gif/631c5dcba1b6f849c32d52acbe68e55b/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr5/THUMBNAIL/image/gif/631c5dcba1b6f849c32d52acbe68e55b/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19680</xocs:filesize>
               <xocs:pixel-height>163</xocs:pixel-height>
               <xocs:pixel-width>165</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/fx2/THUMBNAIL/image/gif/a43b59f456fc06056e781956a1f97ba6/fx2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/fx2/THUMBNAIL/image/gif/a43b59f456fc06056e781956a1f97ba6/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6883</xocs:filesize>
               <xocs:pixel-height>57</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr10.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr10/THUMBNAIL/image/gif/d6743f7b16fdf4747113be3f9132c1ad/gr10.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr10/THUMBNAIL/image/gif/d6743f7b16fdf4747113be3f9132c1ad/gr10.sml</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16794</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr11.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr11/THUMBNAIL/image/gif/425a5a0314e0b8586c7fe702afac714c/gr11.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr11/THUMBNAIL/image/gif/425a5a0314e0b8586c7fe702afac714c/gr11.sml</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16407</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>192</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr2/THUMBNAIL/image/gif/3ec49112d85882a6fde41959b6333094/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr2/THUMBNAIL/image/gif/3ec49112d85882a6fde41959b6333094/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>26168</xocs:filesize>
               <xocs:pixel-height>142</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr9/THUMBNAIL/image/gif/79cd1ad0f005b7caa9ded4835c1d9625/gr9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr9/THUMBNAIL/image/gif/79cd1ad0f005b7caa9ded4835c1d9625/gr9.sml</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13827</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/fx1/THUMBNAIL/image/gif/2093e79a33fd857c260e41a8f909bf8b/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/fx1/THUMBNAIL/image/gif/2093e79a33fd857c260e41a8f909bf8b/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12198</xocs:filesize>
               <xocs:pixel-height>66</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr4/THUMBNAIL/image/gif/034a794918ea020c2a396243d64de24b/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr4/THUMBNAIL/image/gif/034a794918ea020c2a396243d64de24b/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>16842</xocs:filesize>
               <xocs:pixel-height>72</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr1/THUMBNAIL/image/gif/218da3f0e82c96605358952bf5318812/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr1/THUMBNAIL/image/gif/218da3f0e82c96605358952bf5318812/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19115</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr6/THUMBNAIL/image/gif/60503b96f41a54ddcf8d02ecb685e342/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr6/THUMBNAIL/image/gif/60503b96f41a54ddcf8d02ecb685e342/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>23661</xocs:filesize>
               <xocs:pixel-height>146</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr8/THUMBNAIL/image/gif/c41c127f6fd2d389c74d4d26362cbfdd/gr8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr8/THUMBNAIL/image/gif/c41c127f6fd2d389c74d4d26362cbfdd/gr8.sml</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14597</xocs:filesize>
               <xocs:pixel-height>101</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr7/DOWNSAMPLED/image/jpeg/46966030786946cbc512ba01f3a34852/gr7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr7/DOWNSAMPLED/image/jpeg/46966030786946cbc512ba01f3a34852/gr7.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr7</xocs:file-basename>
               <xocs:filename>gr7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>34745</xocs:filesize>
               <xocs:pixel-height>195</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/sc1/DOWNSAMPLED/image/jpeg/068bf04312f4450023d4629acb0e41e0/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/sc1/DOWNSAMPLED/image/jpeg/068bf04312f4450023d4629acb0e41e0/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>70390</xocs:filesize>
               <xocs:pixel-height>398</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr3/DOWNSAMPLED/image/jpeg/f436a5a6b30b8e9bc114573eb263098b/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr3/DOWNSAMPLED/image/jpeg/f436a5a6b30b8e9bc114573eb263098b/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>174288</xocs:filesize>
               <xocs:pixel-height>614</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr5/DOWNSAMPLED/image/jpeg/3c1b80d5f83f9c7227ec33da290d748b/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr5/DOWNSAMPLED/image/jpeg/3c1b80d5f83f9c7227ec33da290d748b/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>76371</xocs:filesize>
               <xocs:pixel-height>530</xocs:pixel-height>
               <xocs:pixel-width>535</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/fx2/DOWNSAMPLED/image/jpeg/647555b90326c152cb9b2e9dd904b3f5/fx2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/fx2/DOWNSAMPLED/image/jpeg/647555b90326c152cb9b2e9dd904b3f5/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20735</xocs:filesize>
               <xocs:pixel-height>98</xocs:pixel-height>
               <xocs:pixel-width>373</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr10.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr10/DOWNSAMPLED/image/jpeg/156b8da6572d0bd9af14c5bb5d7c18ae/gr10.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr10/DOWNSAMPLED/image/jpeg/156b8da6572d0bd9af14c5bb5d7c18ae/gr10.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr10</xocs:file-basename>
               <xocs:filename>gr10.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51741</xocs:filesize>
               <xocs:pixel-height>256</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr11.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr11/DOWNSAMPLED/image/jpeg/202e19ebc0913c1a8cd0e75f4d7f4765/gr11.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr11/DOWNSAMPLED/image/jpeg/202e19ebc0913c1a8cd0e75f4d7f4765/gr11.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr11</xocs:file-basename>
               <xocs:filename>gr11.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64745</xocs:filesize>
               <xocs:pixel-height>476</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr2/DOWNSAMPLED/image/jpeg/7eb1c90dc871187336c2a3068ea110ce/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr2/DOWNSAMPLED/image/jpeg/7eb1c90dc871187336c2a3068ea110ce/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>81278</xocs:filesize>
               <xocs:pixel-height>362</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr9/DOWNSAMPLED/image/jpeg/07fd601c904346c0e3aeb51fec38cfc2/gr9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr9/DOWNSAMPLED/image/jpeg/07fd601c904346c0e3aeb51fec38cfc2/gr9.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr9</xocs:file-basename>
               <xocs:filename>gr9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>53507</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>580</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/fx1/DOWNSAMPLED/image/jpeg/828aa05133fd4e17e6eae62e0be72cf7/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/fx1/DOWNSAMPLED/image/jpeg/828aa05133fd4e17e6eae62e0be72cf7/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40474</xocs:filesize>
               <xocs:pixel-height>151</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr4/DOWNSAMPLED/image/jpeg/2dfafa5c62ce1db3fa72bca75a4c6b32/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr4/DOWNSAMPLED/image/jpeg/2dfafa5c62ce1db3fa72bca75a4c6b32/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51830</xocs:filesize>
               <xocs:pixel-height>182</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr1/DOWNSAMPLED/image/jpeg/93a3a94705778c707332caa33d5607c6/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr1/DOWNSAMPLED/image/jpeg/93a3a94705778c707332caa33d5607c6/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64709</xocs:filesize>
               <xocs:pixel-height>313</xocs:pixel-height>
               <xocs:pixel-width>557</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr6/DOWNSAMPLED/image/jpeg/52f226ca360a1dd3ff73d68fbdf751e4/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr6/DOWNSAMPLED/image/jpeg/52f226ca360a1dd3ff73d68fbdf751e4/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>46769</xocs:filesize>
               <xocs:pixel-height>253</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-gr8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/gr8/DOWNSAMPLED/image/jpeg/bebe36eb0c3e3c45ef8ef0388e3e8c4b/gr8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/gr8/DOWNSAMPLED/image/jpeg/bebe36eb0c3e3c45ef8ef0388e3e8c4b/gr8.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr8</xocs:file-basename>
               <xocs:filename>gr8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>73671</xocs:filesize>
               <xocs:pixel-height>297</xocs:pixel-height>
               <xocs:pixel-width>646</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523416308042-mmc1.docx</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523416308042/mmc1/MAIN/application/msword/c4de3d0b83af0edc688efec1636efe38/mmc1.docx</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523416308042/mmc1/MAIN/application/msword/c4de3d0b83af0edc688efec1636efe38/mmc1.docx</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.docx</xocs:filename>
               <xocs:extension>docx</xocs:extension>
               <xocs:filesize>58098192</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.4" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>8934</aid>
            <ce:pii>S0223-5234(16)30804-2</ce:pii>
            <ce:doi>10.1016/j.ejmech.2016.09.068</ce:doi>
            <ce:copyright type="full-transfer" year="2016">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">The binding mode of BTP and STAT3 SH2 domain by AutoDock4.2.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0015">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:href="pii:S0223523416308042/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">Design strategy of the new STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 2</ce:alt-text>
               <ce:link locator="gr2" xlink:type="simple" xlink:href="pii:S0223523416308042/gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="fspara0020" view="all">The selection of the most suitable linker by docking experiments. Two fragments, BTP and benzene, were merged by different linkers derived from known STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Fig. 3</ce:alt-text>
               <ce:link locator="gr3" xlink:type="simple" xlink:href="pii:S0223523416308042/gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption id="cap0025">
                  <ce:simple-para id="fspara0025" view="all">Docking model of <ce:bold>15</ce:bold> binding to the STAT3 SH2 domain (PDB <ce:inter-ref xlink:href="pdb:1BG1" id="intref0020" xlink:type="simple">1BG1</ce:inter-ref>), generated by AutoDock4.2, carbon atoms of <ce:bold>15</ce:bold> were colored magenta (A) and (B) viewed by Discovery studio, carbon atoms of <ce:bold>15</ce:bold> were colored gray. The key residues were shown. Hydrogen bonds were shown as dashed lines and cation-π interactions were shown as green lines. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0030">Fig. 4</ce:alt-text>
               <ce:link locator="gr4" xlink:type="simple" xlink:href="pii:S0223523416308042/gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption id="cap0030">
                  <ce:simple-para id="fspara0030" view="all">Compound <ce:bold>15</ce:bold> inhibited STAT3 activation. (A and B) Western blot analysis of p-STAT3, STAT3 and IL-6 induced p-STAT3 levels in whole-cell lysates of equal total protein prepared from MDA-MB-231 cells treated with compound <ce:bold>15</ce:bold> for 24 h (C) EMSA analysis of nuclear extracts of equal total protein containing activated STAT3 from MDA-MB-231 cells treated with compound <ce:bold>15</ce:bold> for 24 h after incubation with hSIE probe that binds STAT3.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0035">Fig. 5</ce:alt-text>
               <ce:link locator="gr5" xlink:type="simple" xlink:href="pii:S0223523416308042/gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption id="cap0035">
                  <ce:simple-para id="fspara0035" view="all">Effects of compound <ce:bold>15</ce:bold> on upstream tyrosine kinases p-Jak2 and p-Src and bypass tyrosine kinase p-Erk. Western blot analysis of p-Jak2, Jak2, p-Src, Src and p-Erk levels in whole-cell lysates of equal total protein prepared from MDA-MB-231 cells treated with compound <ce:bold>15</ce:bold> for 24 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0040">Fig. 6</ce:alt-text>
               <ce:link locator="gr6" xlink:type="simple" xlink:href="pii:S0223523416308042/gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="fig7">
               <ce:label>Fig. 7</ce:label>
               <ce:caption id="cap0040">
                  <ce:simple-para id="fspara0040" view="all">Effects of compound <ce:bold>15</ce:bold> on the expression of downstream gene, Bcl-2 and the levels of Cleaved-PARP and Cleaved-Caspase 3. Western blot analysis of Bcl-2, Cleaved-PARP and Cleaved-Caspase 3 levels in whole-cell lysates of equal total protein prepared from MDA-MB-231 cells treated with compound <ce:bold>15</ce:bold> for 24 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0045">Fig. 7</ce:alt-text>
               <ce:link locator="gr7" xlink:type="simple" xlink:href="pii:S0223523416308042/gr7"/></ce:link>
            </ce:figure>
            <ce:figure id="fig8">
               <ce:label>Fig. 8</ce:label>
               <ce:caption id="cap0045">
                  <ce:simple-para id="fspara0045" view="all">Compound <ce:bold>15</ce:bold> induced human carcinoma MDA-MB-231 cells apoptosis <ce:italic>in Vitro</ce:italic>. MDA-MB-231 cells were incubated with <ce:bold>15</ce:bold> at different concentrations for 24 h. Annexin V-FITC/PI staining was carried out and the percentages of apoptotic cells were further determined using flow cytometry. ***p < 0.001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0050">Fig. 8</ce:alt-text>
               <ce:link locator="gr8" xlink:type="simple" xlink:href="pii:S0223523416308042/gr8"/></ce:link>
            </ce:figure>
            <ce:figure id="fig9">
               <ce:label>Fig. 9</ce:label>
               <ce:caption id="cap0050">
                  <ce:simple-para id="fspara0050" view="all">Compound <ce:bold>15</ce:bold> induced ROS generation. MDA-MB-231 cells were incubated with <ce:bold>15</ce:bold> at different concentrations for 24 h, and then cells were collected and stained by DCFH-DA and subjected to flow cytometry. ***p < 0.001, **p < 0.01.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0055">Fig. 9</ce:alt-text>
               <ce:link locator="gr9" xlink:type="simple" xlink:href="pii:S0223523416308042/gr9"/></ce:link>
            </ce:figure>
            <ce:figure id="fig10">
               <ce:label>Fig. 10</ce:label>
               <ce:caption id="cap0055">
                  <ce:simple-para id="fspara0055" view="all">Compound <ce:bold>15</ce:bold> inhibited the colony formation of MDA-MB-231 carcinoma cells. MDA-MB-231 cells were treated with compound <ce:bold>15</ce:bold> at 0.5–6 μM for 24 h and cultured for 14 d until the colonies were visible. Crystal violet solution was used to stain the colonies for 4 h and imaged. ***p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0060">Fig. 10</ce:alt-text>
               <ce:link locator="gr10" xlink:type="simple" xlink:href="pii:S0223523416308042/gr10"/></ce:link>
            </ce:figure>
            <ce:figure id="fig11">
               <ce:label>Fig. 11</ce:label>
               <ce:caption id="cap0060">
                  <ce:simple-para id="fspara0060" view="all">Compound <ce:bold>15</ce:bold> inhibited the growth of mouse sarcoma xenograft tumors <ce:italic>in vivo</ce:italic>. (A) The weight of tumor tissues of the treated and control mice. (B) Western blot analysis of p-STAT3 and STAT3 levels in tumor tissues prepared from control (C1, C2) or mice treated with DOX (D1, D2) or compound <ce:bold>15</ce:bold> (15-1, 15-2). (C) The growing curves of mice's body weight. (D) The mice's body weight before sacrificed. ***p < 0.001.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0065">Fig. 11</ce:alt-text>
               <ce:link locator="gr11" xlink:type="simple" xlink:href="pii:S0223523416308042/gr11"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:caption id="cap0065">
                  <ce:simple-para id="fspara0065" view="all">Synthesis of 6 or 7-substituted aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides. Reagents and conditions: (a) HSCH<ce:inf loc="post">2</ce:inf>COOCH<ce:inf loc="post">3,</ce:inf> DMF, 60 °C, 16 h; (b) 10% KOH, reflux, 3 h, 1 M HCl; (c) Ag<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf>, DMSO, reflux, 16 h; (d) m-CPBA, DCM, reflux, 8 h; (e) Pd(OAc)<ce:inf loc="post">2,</ce:inf> Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3,</ce:inf> BINAP, toluene, reflux, 4–48 h.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0070">Scheme 1</ce:alt-text>
               <ce:link locator="sc1" xlink:type="simple" xlink:href="pii:S0223523416308042/sc1"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0070">
                  <ce:simple-para id="tspara0010" view="all">Antiproliferative activity of the designed compounds and reference Stattic<ce:display>
                        <ce:figure id="dfig1">
                           <ce:alt-text role="short" id="alttext0075">Image 2</ce:alt-text>
                           <ce:link locator="fx2" xlink:type="simple" xlink:href="pii:S0223523416308042/fx2"/></ce:link>
                        </ce:figure>
                     </ce:display>.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0080">Table 1</ce:alt-text>
               <tgroup cols="7">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">Compd</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1">R</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col3" nameend="col4">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A549</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">HCT-116</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col3" nameend="col7">IC<inf loc="post">50</inf> ± SD (μM)<cross-ref refid="tbl1fna" id="crosref0185">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>6</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.31 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.44 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.50 ± 0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.37 ± 0.36</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>7</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.30 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.14 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.27 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.34 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-CN</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.40 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.22 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.21 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.17 ± 0.09</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.72 ± 1.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.30 ± 0.17</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.67 ± 1.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.44 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>11</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-Cl<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.89 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">3.32 ± 0.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.23 ± 0.51</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.47 ± 0.25</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-F<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.05 ± 0.43</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.55 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.61 ± 0.82</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.02 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4,5-(OCH<inf loc="post">3</inf>)<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.43 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.88 ± 0.33</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.23 ± 0.16</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.42 ± 0.13</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>14</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-OCF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.08 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.37 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.02 ± 0.34</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.98 ± 0.55</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>15</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.68 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">0.36 ± 0.02</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.75 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.33 ± 0.04</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>16</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OCF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.10 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.57 ± 0.08</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.69 ± 0.23</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.38 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>17</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4,5-(OCH<inf loc="post">3</inf>)<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.99 ± 0.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">0.95 ± 0.04</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.93 ± 0.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.15 ± 0.15</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>18</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.20 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.44 ± 0.15</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.82 ± 0.19</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.44 ± 0.11</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-Cl</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.21 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">1.04 ± 0.05</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.68 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.26 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,5-(CH<inf loc="post">3</inf>)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.12 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">4.80 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.80 ± 2.30</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">F<inf loc="post">5</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.46 ± 1.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">3.48 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.30 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.37 ± 0.22</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3-F</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.91 ± 0.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.55 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.12 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.22 ± 0.18</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-CH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.56 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.68 ± 0.42</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.89 ± 0.27</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4.00 ± 0.42</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>24</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">4-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.04 ± 0.03</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.59 ± 0.32</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.94 ± 0.14</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.99 ± 0.23</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>25</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-OCH<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.40 ± 0.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.59 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.10 ± 1.40</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.00 ± 1.21</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>26</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-F<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.89 ± 0.11</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">2.50 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.95 ± 0.28</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.68 ± 0.08</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>27</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,4-Cl<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.36 ± 0.09</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">0.66 ± 0.01</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.57 ± 0.18</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.68 ± 0.14</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>28</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3,5-(CF<inf loc="post">3</inf>)<inf loc="post">2</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.12 ± 0.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">3.84 ± 0.36</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.11 ± 1.60</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.60 ± 0.81</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>29</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2-CF<inf loc="post">3</inf>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.90 ± 0.22</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">4.12 ± 0.13</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.10 ± 3.10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">5.95 ± 0.61</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>Stattic</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd"/></entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.68 ± 0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col5">4.40 ± 0.88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.36 ± 0.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.08 ± 0.31</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para id="ntpara0010" view="all">The inhibitory effects of the compounds on the proliferation of the four cell lines were determined by the MTT assay. SD: standard deviation, all experiments were independently performed at least three times.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Research paper</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Antagonizing STAT3 activation with benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide based small molecules</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1">
                  <ce:given-name>Wenda</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
               </ce:author>
               <ce:author id="au2">
                  <ce:given-name>Ting</ce:given-name>
                  <ce:surname>Ma</ce:surname>
               </ce:author>
               <ce:author id="au3">
                  <ce:given-name>Shanshan</ce:given-name>
                  <ce:surname>Li</ce:surname>
               </ce:author>
               <ce:author id="au4">
                  <ce:given-name>Yanwei</ce:given-name>
                  <ce:surname>Yang</ce:surname>
               </ce:author>
               <ce:author id="au5" orcid="0000-0002-0811-0269">
                  <ce:given-name>Jianpeng</ce:given-name>
                  <ce:surname>Guo</ce:surname>
               </ce:author>
               <ce:author id="au6" orcid="0000-0002-4791-8615">
                  <ce:given-name>Wenying</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref refid="cor2" id="crosref0010">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au7">
                  <ce:given-name>Lingyi</ce:given-name>
                  <ce:surname>Kong</ce:surname>
                  <ce:cross-ref refid="cor1" id="crosref0015">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:textfn>State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing 210009, People's Republic of China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>State Key Laboratory of Natural Medicines</sa:organization>
                     <sa:organization>Department of Natural Medicinal Chemistry</sa:organization>
                     <sa:organization>China Pharmaceutical University</sa:organization>
                     <sa:address-line>24 Tong Jia Xiang</sa:address-line>
                     <sa:city>Nanjing</sa:city>
                     <sa:postal-code>210009</sa:postal-code>
                     <sa:country>People's Republic of China</sa:country>
                  </sa:affiliation>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
            </ce:author-group>
            <ce:date-received day="24" month="5" year="2016"/></ce:date-received>
            <ce:date-revised day="20" month="9" year="2016"/></ce:date-revised>
            <ce:date-accepted day="21" month="9" year="2016"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">STAT3 is an attractive therapeutic target for cancer therapy. However, due to low potency or poor druggability, none of its inhibitors are clinically available. Herein, a series of aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides with good drug-likeness properties were designed, synthesized and evaluated as STAT3 inhibitors. Most of them exhibited higher antitumor activity than the small-molecule STAT3 inhibitor, Stattic. Compound <ce:bold>15</ce:bold> was the most potent and had an IC<ce:inf loc="post">50</ce:inf> range in 0.33–0.75 μM in various cancer cell lines. The overexpressed and IL-6 induced phosphorylation levels of STAT3 were both inhibited by <ce:bold>15</ce:bold> without influencing the phosphorylation levels of the upstream kinases Src and Jak2. <ce:bold>15</ce:bold> also suppressed the expressions of STAT3 downstream gene, Bcl-2. <ce:bold>15</ce:bold> effectively increased the ROS levels of cancer cells, induced cancer cell apoptosis and abolished the colony formation ability of cancer cells without affecting bypass kinase p-Erk. Furthermore, <ce:bold>15</ce:bold> 
                     <ce:italic>in vivo</ce:italic> induced significant antitumor responses, and exhibited less toxicity than Doxorubicin. Together, this study described a class of new STAT3 inhibitors as antitumor agents.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">Compound <ce:bold>15</ce:bold> selectively inhibited STAT3 activation to exert antitumor activity.<ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:href="pii:S0223523416308042/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>Antitumor agents</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Drug-likeness properties</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>STAT3 phosphorylation, Apoptosis</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords xml:lang="en" class="abr" id="kwrds0015" view="all">
               <ce:section-title id="sectitle0030">Abbreviations used</ce:section-title>
               <ce:keyword id="kwrd0030">
                  <ce:text>DMSO</ce:text>
                  <ce:keyword id="kwrd0035">
                     <ce:text>dimethyl sulfoxide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0040">
                  <ce:text>AKT</ce:text>
                  <ce:keyword id="kwrd0045">
                     <ce:text>a serine/threonine protein kinase</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0050">
                  <ce:text>Erk</ce:text>
                  <ce:keyword id="kwrd0055">
                     <ce:text>extracellular regulated kinase</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0060">
                  <ce:text>rt</ce:text>
                  <ce:keyword id="kwrd0065">
                     <ce:text>room temperature</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0070">
                  <ce:text>MTT</ce:text>
                  <ce:keyword id="kwrd0075">
                     <ce:text>3-4,5-dehyl-al-2-y]-2,5-dphnetrazolium bromide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0080">
                  <ce:text>SH2</ce:text>
                  <ce:keyword id="kwrd0085">
                     <ce:text>Src homology 2</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0090">
                  <ce:text>STAT</ce:text>
                  <ce:keyword id="kwrd0095">
                     <ce:text>signal transducer and activator of transcription</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0100">
                  <ce:text>PI</ce:text>
                  <ce:keyword id="kwrd0105">
                     <ce:text>propidium iodide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword id="kwrd0110">
                  <ce:text>GAPDH</ce:text>
                  <ce:keyword id="kwrd0115">
                     <ce:text>glyceraldehyde-3-phosphatedehydrogenase</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0035">Introduction</ce:section-title>
                  <ce:para id="p0035" view="all">Signal transducer and activator of transcription 3 (STAT3) is a member of STAT protein family, which includes STAT1, 2, 3, 4, 5a, 5b and 6. STAT3 is closely associated with the occurrence of cancers <ce:cross-ref refid="bib1" id="crosref0020">[1]</ce:cross-ref>. Especially, aberrantly activated STAT3 has been found in numerous cancers such as breast, prostate, lung, ovarian, leukemia and lymphoma cancers <ce:cross-refs refid="bib2 bib3 bib4 bib5 bib6" id="crosrefs0010">[2–6]</ce:cross-refs>. STAT3 is widely regarded as a master regulator of the cellular events which is correlated with cell proliferation, differentiation, apoptosis, angiogenesis and immune response <ce:cross-refs refid="bib7 bib8 bib9 bib10 bib11 bib12" id="crosrefs0015">[7–12]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0040" view="all">STAT3 can be phosphorylated at Tyr705 and then be activated which is mediated by the cytoplasmic kinases such as Janus kinases (Jaks) and Src family kinases <ce:cross-refs refid="bib11 bib13" id="crosrefs0020">[11,13]</ce:cross-refs>. Two phosphorylated STAT3 proteins form homo-dimeric activated transcription factor complex <ce:italic>via</ce:italic> reciprocal binding of pTyr-SH2 domains. The p-STAT3 dimers translocate to the nucleus, where they bind to DNA and induce target gene expression <ce:cross-refs refid="bib5 bib11 bib12 bib13 bib14" id="crosrefs0025">[5,11–14]</ce:cross-refs>. More evidences have shown that the constitutive activation of STAT3 plays an essential role in cancer cell growth and survival and inhibiting the activation of STAT3 may be a novel and powerful weapon in the cancer therapies <ce:cross-refs refid="bib15 bib16 bib17 bib18 bib19" id="crosrefs0030">[15–19]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0045" view="all">Over the past decade, several strategies have been explored to directly or indirectly target and inhibit STAT3, which are: (a) the direct inhibitors targeting the SH2 domain or dimerization of STAT3 (such as LY5 <ce:cross-ref refid="bib5" id="crosref0025">[5]</ce:cross-ref>, STA-21 <ce:cross-ref refid="bib20" id="crosref0030">[20]</ce:cross-ref>, LLL12 <ce:cross-refs refid="bib21 bib22 bib23" id="crosrefs0035">[21–23]</ce:cross-refs>, Cryptotanshinone <ce:cross-ref refid="bib24" id="crosref0035">[24]</ce:cross-ref>, Stattic <ce:cross-ref refid="bib25" id="crosref0040">[25]</ce:cross-ref>, Niclosamide <ce:cross-refs refid="bib26 bib27" id="crosrefs0040">[26,27]</ce:cross-refs>, HJC0146 <ce:cross-ref refid="bib28" id="crosref0045">[28]</ce:cross-ref>, BP-1-102 <ce:cross-ref refid="bib29" id="crosref0050">[29]</ce:cross-ref>), the inhibitors targeting the DNA binding domain (such as S3-54A18) <ce:cross-ref refid="bib30" id="crosref0055">[30]</ce:cross-ref>, and the inhibitors targeting the N-terminal domain (a category of short peptides) <ce:cross-refs refid="bib31 bib32" id="crosrefs0045">[31,32]</ce:cross-refs>; and (b) the indirect inhibitors targeting the upstream kinases or factors on the STAT3 pathway (such as resveratrol <ce:cross-ref refid="bib33" id="crosref0060">[33]</ce:cross-ref>, curcumin <ce:cross-refs refid="bib34 bib35" id="crosrefs0050">[34,35]</ce:cross-refs>). However, there's still no STAT3 inhibitor available in the market. The challenges include the lack of membrane permeability and stability, low water-solubility, weak binding affinity, or low specificity. Therefore, discovery of novel potent and druggable STAT3 inhibitors is still highly valuable.</ce:para>
                  <ce:para id="p0050" view="all">The benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (BTP) moiety is a crucial pharmacophore of many STAT3 inhibitors (such as Stattic, HJC0123 and HJC0146), which not only significantly inhibited STAT3 phosphorylation but also markedly exhibited anti-proliferative activity <ce:cross-refs refid="bib20 bib22 bib28 bib36" id="crosrefs0055">[20,22,28,36]</ce:cross-refs>. Besides, compounds with BTP moiety could increase ROS levels in cancer cells, which further induced cancer cell apoptosis. What's more, its low molecular weight is more feasible for further optimization. In view of this, we were promoted to use this fragment as a starting point for the design of novel antitumor STAT3 inhibitors.</ce:para>
                  <ce:para id="p0055" view="all">Using structure-based drug design methods, we discovered 6 or 7-substituted aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides as a new series of STAT3 inhibitors with potent antitumor activity. These new inhibitors are promising candidates for further drug development, due to their drug-like properties and potent bioactivity <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>.</ce:para>
               </ce:section>
               <ce:section id="sec2" role="results" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0040">Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0045">Design</ce:section-title>
                     <ce:para id="p0060" view="all">Initially, BTP was docked into STAT3 protein (PDB: <ce:inter-ref xlink:href="pdb:1BG1" id="intref0010" xlink:type="simple">1BG1</ce:inter-ref>) and the binding mode was carefully analyzed by AutoDock4.2 software. As shown in <ce:cross-ref refid="fig1" id="crosref0065">Fig. 1</ce:cross-ref>
                        <ce:float-anchor refid="fig1"/></ce:float-anchor>, this planner scaffold only occupied in the essential pTyr705 binding site by forming three hydrogen bonds with residues Arg609, Ser611 and Ser613. In order to increase the binding affinity of the designed compounds, we were promoted to introduce fragments at the C6 or C7 position of BTP and to develop BTP derivatives binding to two “hot spots” of STAT3 SH2 domain (pTyr705 binding site and side pocket) (<ce:cross-ref refid="fig2" id="crosref0070">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>) <ce:cross-ref refid="bib5" id="crosref0075">[5]</ce:cross-ref>. Aiming to target the side pocket of STAT3, according to docking the poses of known inhibitors, substituted aromatic benzene rings were introduced to fit the side pocket. To search for suitable linkers, benzene ring was initially introduced to the BTP fragment. Linkers were chosen from the known inhibitors. Then, the merged potential candidates were quickly screened <ce:italic>via</ce:italic> computational docking for the final decision of the most suitable linker (<ce:cross-ref refid="fig3" id="crosref0080">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>). The criteria are as follows: (1) the linker should maintain the binding of BTP to the pTyr705 site and ensure the new introduced fragments fitting in the side pocket as well; (2) the linker should be as simple and small-size as possible according to the theory of ligand efficiency, the smaller the linker is, the higher the LE is; (3) the linker should be feasible for synthesis. Finally, a secondary amine was chosen as the linker to evolve new STAT3 inhibitors.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0050">Chemistry</ce:section-title>
                     <ce:para id="p0065" view="all">The synthetic routes for compounds <ce:bold>6–29</ce:bold> were shown in <ce:cross-ref refid="sch1" id="crosref0085">Scheme 1</ce:cross-ref>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>. <ce:bold>2a</ce:bold> or <ce:bold>2b</ce:bold> was obtained by the reaction of commercially available 3-bromo-2-fluorobenzaldehyde (<ce:bold>1a</ce:bold>) or 4-bromo-2-fluorobenzaldehyde (<ce:bold>1b</ce:bold>) and methyl thioglycolate catalyzed by potassium carbonate. Compound <ce:bold>2a</ce:bold> or <ce:bold>2b</ce:bold> was hydrolyzed in 10% potassium hydroxide solution and acidified by concentrated hydrochloric acid to produce <ce:bold>3a</ce:bold> or <ce:bold>3b</ce:bold>. Compound <ce:bold>4a</ce:bold> or <ce:bold>4b</ce:bold> was obtained by the decarboxylation of <ce:bold>3a</ce:bold> or <ce:bold>3b</ce:bold>, which was then reacted with 3-chlorine peroxide benzoic acid for the synthesis of <ce:bold>5a</ce:bold> or <ce:bold>5b</ce:bold>. Compounds <ce:bold>6–29</ce:bold> were obtained by Buchwald--Hartwig C<ce:glyph name="sbnd"/></ce:glyph>N coupling reaction of <ce:bold>5a</ce:bold> or <ce:bold>5b</ce:bold> using different anilines. All of the BTP derivatives were confirmed by <ce:sup loc="pre">1</ce:sup>H NMR, IR, HRMS (ESI) spectra, and <ce:sup loc="pre">13</ce:sup>C NMR spectrum.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0055">Biological evaluation</ce:section-title>
                     <ce:section id="sec2.3.1" view="all">
                        <ce:label>2.3.1</ce:label>
                        <ce:section-title id="sectitle0060">In vitro cell growth inhibitory activity</ce:section-title>
                        <ce:para id="p0070" view="all">To summarize the structure-activity relationships of the synthetic compounds, four STAT3 over-activated human cancer cell lines, including lung carcinoma A549, breast carcinoma MDA-MB-231 and MCF-7 and colon carcinoma HCT116, were treated with designed compounds and the positive control, Stattic, by MTT assay. The IC<ce:inf loc="post">50</ce:inf> values were summarized in <ce:cross-ref refid="tbl1" id="crosref0090">Table 1</ce:cross-ref>
                           <ce:float-anchor refid="tbl1"/></ce:float-anchor>. Notably, most of the compounds exhibited better activity than Stattic. The IC<ce:inf loc="post">50</ce:inf> values were within 0.26–4.40 μM. Among them, the most potent compound <ce:bold>15</ce:bold> inhibited the growth of MDA-MB-231, A549, MCF-7, and HCT116 cells with IC<ce:inf loc="post">50</ce:inf> values of 0.68, 0.36, 0.75, and 0.33 μM, which had 1.5- to 12-fold improvement in activity than Stattic, respectively. Compound <ce:bold>19</ce:bold> possessing a 4′-Cl was 1.4- to 7.2-fold more potent than the reference Stattic in four tested cell lines. Comparison of the two series of compounds, generally, 7-substituted aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides were more potent than 6-substituted compounds. The substitution of aniline groups significantly contributed to the antitumor activity. In general, the compounds with electron-withdrawing group such as chlorine (<ce:bold>11</ce:bold>, <ce:bold>19</ce:bold> and <ce:bold>27</ce:bold>), fluorine (<ce:bold>12</ce:bold> and <ce:bold>26</ce:bold>), or trifluoromethyl group (<ce:bold>6</ce:bold>, <ce:bold>7</ce:bold>, <ce:bold>15</ce:bold> and <ce:bold>18</ce:bold>) usually showed better inhibitory activity than those with electron-donating group such as cyano (<ce:bold>8</ce:bold>) or methyl groups (<ce:bold>20</ce:bold> and <ce:bold>23</ce:bold>). Replacement of a hydrogen atom with methoxy or trifluoromethoxy group at 3′ or 4′ position (<ce:bold>9</ce:bold>, <ce:bold>14</ce:bold>, <ce:bold>16</ce:bold> and <ce:bold>24</ce:bold>) was tolerated but 2′-OCH<ce:inf loc="post">3</ce:inf> in compound <ce:bold>25</ce:bold> led to a slight decrease in activity. And replacement with three methoxy groups at 3′, 4′ and 5′ position in compound <ce:bold>13</ce:bold> and <ce:bold>17</ce:bold> increased the activity. Adding a chlorine at C3′, as in compound <ce:bold>27</ce:bold>, led to a slight decrease of anti-proliferative activity as compared to <ce:bold>19</ce:bold> indicating that C3′-Cl was not favored. Compounds (<ce:bold>6</ce:bold>, <ce:bold>7</ce:bold>, <ce:bold>15</ce:bold>, and <ce:bold>18)</ce:bold> with trifluoromethyl group showed an improvement in the anti-proliferative activity, however, the activity of <ce:bold>28</ce:bold> or <ce:bold>29</ce:bold> led to a slight decrease.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.2" view="all">
                        <ce:label>2.3.2</ce:label>
                        <ce:section-title id="sectitle0065">Molecular docking</ce:section-title>
                        <ce:para id="p0075" view="all">To further understand the structure-activity relationship, the potential binding modes of all compounds with the STAT3 SH2 domain were predicted by docking experiments. Most compounds could bind to the pTyr705 site and the side pocket well, except of the 2′ or 3′, 5’-substituted compound <ce:bold>25</ce:bold>, <ce:bold>28</ce:bold> and <ce:bold>29</ce:bold> due to the steric hindrance of the substituents to the side pocket (<ce:cross-ref refid="appsec1" id="crosref0095">Fig. S1</ce:cross-ref>), which reasonably explained their decreasing bioactivity. As shown in <ce:cross-ref refid="fig4" id="crosref0100">Fig. 4</ce:cross-ref>
                           <ce:float-anchor refid="fig4"/></ce:float-anchor>, the representative compound <ce:bold>15</ce:bold> could bind tightly to the STAT3 SH2 domain by forming four hydrogen bonding interactions with the Arg609, Lys591 and Ser636 residues. In addition, its 3’-trifluoromethylaniline could fit deeply into the side pocket. Furthermore, it also formed two cation-π interactions with Lys591 and Arg609 (one was formed by the charged amine of Lys591 residue to the phenyl ring of BTP and the other was formed by the charged amine of Arg609 residue to C7 position of the other phenyl group) providing a rationale explaining the best activity of compound <ce:bold>15</ce:bold> among all.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.3" view="all">
                        <ce:label>2.3.3</ce:label>
                        <ce:section-title id="sectitle0070">compound <ce:bold>15</ce:bold> inhibited STAT3 activity in tumor cells</ce:section-title>
                        <ce:para id="p0080" view="all">To evaluate whether these compounds were STAT3 inhibitors, the most potent compound <ce:bold>15</ce:bold> was selected to study its antitumor mechanism. Firstly, the effect of <ce:bold>15</ce:bold> on the p-STAT3 levels was investigated by western blot analysis. MDA-MB-231 cells were incubated with <ce:bold>15</ce:bold> (1–5 μM) or Stattic (5 μM) for 24 h and the levels of p-STAT3 and total STAT3 were then examined. It was found that compound <ce:bold>15</ce:bold> markedly suppressed STAT3 phosphorylation at Tyr705 residue in a concentration-dependent manner, but had no effect on the total STAT3 (<ce:cross-ref refid="fig5" id="crosref0105">Fig. 5</ce:cross-ref>
                           <ce:float-anchor refid="fig5"/></ce:float-anchor>A).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.4" view="all">
                        <ce:label>2.3.4</ce:label>
                        <ce:section-title id="sectitle0075">Compound <ce:bold>15</ce:bold> inhibited STAT3 phosphorylation induced by interleukin-6 (IL-6)</ce:section-title>
                        <ce:para id="p0085" view="all">The effect of <ce:bold>15</ce:bold> on IL-6 induced STAT3 phosphorylation was also assessed as reported <ce:cross-ref refid="bib37" id="crosref0110">[37]</ce:cross-ref>. MDA-MB-231 cells were starved overnight, followed by treatment with <ce:bold>15</ce:bold> for 12 h before IL-6 stimulation. As shown in <ce:cross-ref refid="fig5" id="crosref0115">Fig. 5</ce:cross-ref>B, IL-6 significantly increased the phosphorylation levels of STAT3, which was decreased by <ce:bold>15</ce:bold> in a dose-dependent manner. Compound <ce:bold>15</ce:bold> at 5 μM almost completely abolished STAT3 phosphorylation induced by IL-6.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.5" view="all">
                        <ce:label>2.3.5</ce:label>
                        <ce:section-title id="sectitle0080">Compound <ce:bold>15</ce:bold> inhibited STAT3 DNA-binding activity</ce:section-title>
                        <ce:para id="p0090" view="all">Given the inhibitory effect of <ce:bold>15</ce:bold> on p-STAT3 in tumor cells, we evaluated the inhibitory activity against STAT3 DNA-binding activity by electrophoretic mobility shift assay (EMSA). Nuclear extracts from MDA-MB-231 cells incubated with <ce:bold>15</ce:bold> prior to incubating with hSIE probe and preforming EMSA analysis. STAT3:STAT3/DNA-binding activity was diminished by <ce:bold>15</ce:bold> at a start concentration at 1 μM and an obvious decrease at 5 μM as compared with Stattic at 5 μM (<ce:cross-ref refid="fig5" id="crosref0120">Fig. 5</ce:cross-ref>C).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.6" view="all">
                        <ce:label>2.3.6</ce:label>
                        <ce:section-title id="sectitle0085">Typical upstream or other kinases of STAT3 were not inhibited by <ce:bold>15</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0095" view="all">The activation of STAT3 phosphorylated at Tyr705 may be mediated by upstream kinases (such as Jak2, Src) or other kinases (such as Erk1/2). To investigate the selectivity of <ce:bold>15</ce:bold> targeting p-STAT3, we evaluated the effect of <ce:bold>15</ce:bold> on p-Jak2, p-Src, p-Erk1/2 by western blot analysis. Data showed that compound <ce:bold>15</ce:bold> had no effect on p-Jak2, p-Src, and p-Erk1/2 in MDA-MB-231 cells (<ce:cross-ref refid="fig6" id="crosref0125">Fig. 6</ce:cross-ref>
                           <ce:float-anchor refid="fig6"/></ce:float-anchor>). These results indicated that the inhibition of p-STAT3 by <ce:bold>15</ce:bold> was selective and independent of the above kinases.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.7" view="all">
                        <ce:label>2.3.7</ce:label>
                        <ce:section-title id="sectitle0090">Compound <ce:bold>15</ce:bold> inhibited the expression of the downstream gene of STAT3, Bcl-2, and induced the apoptosis of cancer cells</ce:section-title>
                        <ce:para id="p0100" view="all">We had elucidated that compound <ce:bold>15</ce:bold> could effectively inhibit the activation of STAT3. To further gain more insights into the mechanism of <ce:bold>15</ce:bold> on the STAT3 pathway, we examined its effect on the expressions of STAT3-targeted gene, Bcl-2, and the levels of Cleaved PARP and Cleaved Caspase-3 which are related to apoptosis. MDA-MB-231 cells were treated with compound <ce:bold>15</ce:bold> and processed for western blotting. As shown in <ce:cross-ref refid="fig7" id="crosref0130">Fig. 7</ce:cross-ref>
                           <ce:float-anchor refid="fig7"/></ce:float-anchor>, compound <ce:bold>15</ce:bold> inhibited the expression of Bcl-2 and induced the cleavage of PARP and Caspase-3 in MDA-MB-231 cells.</ce:para>
                        <ce:para id="p0105" view="all">The effect of compound <ce:bold>15</ce:bold> on inducing tumor cell apoptosis was analyzed. MDA-MB-231 cells were incubated with <ce:bold>15</ce:bold> at different concentrations for 24 h. Annexin V-FITC/PI staining was carried out and the percentages of apoptotic cells were further determined using flow cytometry. The results showed that <ce:bold>15</ce:bold> dose-dependently induced the apoptosis of MDA-MB-231 cells. The induced apoptosis rates at 0, 1, 3, 5 and 7 μM were 5.6%, 9.7%, 10.9%, 17.5% and 20.9%, respectively (<ce:cross-ref refid="fig8" id="crosref0135">Fig. 8</ce:cross-ref>
                           <ce:float-anchor refid="fig8"/></ce:float-anchor>). Together, these data showed that compound <ce:bold>15</ce:bold> induced the apoptosis of cancer cells through activating the caspase-dependent pathway relating to Bcl-2, which was regulated by the deactivation of STAT3 protein.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.8" view="all">
                        <ce:label>2.3.8</ce:label>
                        <ce:section-title id="sectitle0095">Compound <ce:bold>15</ce:bold> induced the ROS generation in tumor cells</ce:section-title>
                        <ce:para id="p0110" view="all">It was reported that benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide derivatives could induce the generation of reactive oxygen species, which would partially contribute to the cell apoptosis <ce:cross-ref refid="bib38" id="crosref0140">[38]</ce:cross-ref>. Subsequently, we evaluated the effect of <ce:bold>15</ce:bold> on the ROS levels in tumor cells. MDA-MB-231 cells were incubated with <ce:bold>15</ce:bold> at different concentrations for 24 h, and then cells were collected and stained by DCFH-DA and subjected to flow cytometry. Expectedly, the levels of ROS showed a 1.37, 1.74 or 1.94 fold increase at 1, 3 and 5 μM of <ce:bold>15</ce:bold> (<ce:cross-ref refid="fig9" id="crosref0145">Fig. 9</ce:cross-ref>
                           <ce:float-anchor refid="fig9"/></ce:float-anchor>).</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.9" view="all">
                        <ce:label>2.3.9</ce:label>
                        <ce:section-title id="sectitle0100">Compound <ce:bold>15</ce:bold> inhibited tumor cells colony formation</ce:section-title>
                        <ce:para id="p0115" view="all">To further investigate the anti-proliferative activity of compound <ce:bold>15</ce:bold> on cancer cells, colony survival assay was performed. MDA-MB-231 cells were treated with compound <ce:bold>15</ce:bold> at 0.5–6 μM for 24 h and cultured for 14 d until the colonies were visible. Crystal violet solution (Sigma, St. Louis, MO, USA) was used to stain the colonies for 4 h and imaged. As shown in <ce:cross-ref refid="fig10" id="crosref0150">Fig. 10</ce:cross-ref>
                           <ce:float-anchor refid="fig10"/></ce:float-anchor>, a significant reduction in clonogenic ability at 0.5 and 1.0 μM of compound <ce:bold>15</ce:bold> and an almost cessation of colony formation at 6 μM.</ce:para>
                     </ce:section>
                     <ce:section id="sec2.3.10" view="all">
                        <ce:label>2.3.10</ce:label>
                        <ce:section-title id="sectitle0105">Compound <ce:bold>15</ce:bold> exhibited antitumor activity <ce:italic>in vivo</ce:italic>
                        </ce:section-title>
                        <ce:para id="p0120" view="all">We tested the <ce:italic>in vivo</ce:italic> antitumor efficacy of <ce:bold>15</ce:bold> against mouse breast tumor xenograft. After the solid tumors were established, the mice were randomized and treated intraperitoneally with <ce:bold>15</ce:bold> 10 mg/kg per day, 1 mg/kg of Doxorubicin every four days or the same volume of vehicle consisting of PBS/DMSO (8:2) daily for 11 consecutive days. The tumor weights of mice were both significantly reduced 61% treated with <ce:bold>15</ce:bold> and 67% decrease treated with Doxorubicin (<ce:cross-ref refid="fig11" id="crosref0155">Fig. 11</ce:cross-ref>
                           <ce:float-anchor refid="fig11"/></ce:float-anchor>A), and the p-STAT3 levels in the tumor tissues from mice treated with <ce:bold>15</ce:bold> was also inhibited (<ce:cross-ref refid="fig11" id="crosref0160">Fig. 11</ce:cross-ref>B). However, <ce:bold>15</ce:bold> exhibited much less side effect than Doxorubicin, since dramatic loss of mice body weight was observed from the treated by Doxorubicin, whereas for <ce:bold>15</ce:bold> without any such toxicity (<ce:cross-ref refid="fig11" id="crosref0165">Fig. 11</ce:cross-ref>C and D).</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" role="conclusion" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0110">Conclusions</ce:section-title>
                  <ce:para id="p0125" view="all">In summary, a series of 6 or 7-substituted aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides were designed, synthesized, and biologically evaluated as STAT3 inhibitors. According to our screening results, most of the designed compounds exerted higher antitumor activity than Stattic. SAR analysis indicated that 6 or 7-substituted anilines of aminobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxides were important to the bioactivities. Docking studies revealed that most compounds could tightly bind to the SH2 domain of STAT3 and further provided a rationale for SAR. Especially, <ce:bold>15</ce:bold> was well fitted in the SH2 domain by four hydrogen bonding interactions with the Arg609, Lys591 and Ser636 residues and two cation-π interactions with Lys591 and Arg609 residues, and its additional 7-substituted aniline was deeply buried into the side binding pocket. The most potent compound <ce:bold>15</ce:bold> exhibited remarkable anti-proliferation activity against four cancer lines with an IC<ce:inf loc="post">50</ce:inf> range in 0.33–0.75 μM and was selected to investigate the mechanism of its antitumor activity. It inhibited STAT3 phosphorylation, IL-6 induced STAT3 phosphorylation, STAT3-DNA binding activity and the expression of STAT3 downstream gene, Bcl-2, to induce tumor apoptosis. The increased levels of ROS by <ce:bold>15</ce:bold> further induced the tumor apoptosis and the cessation of the tumor colony formation. Furthermore, <ce:bold>15</ce:bold> 
                     <ce:italic>in vivo</ce:italic> induced significant antitumor responses, and exhibited less toxicity than Doxorubicin. Compared with Stattic, <ce:bold>15</ce:bold> exhibited a significant increase of bioactivity and better binding affinity, which is worth of further investigations toward the discovery of novel STAT3 inhibitors as antitumor drugs.</ce:para>
               </ce:section>
               <ce:section id="sec4" role="materials-methods" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title id="sectitle0115">Materials and methods</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title id="sectitle0120">Chemistry</ce:section-title>
                     <ce:para id="p0130" view="all">All chemicals (reagent grade) used were purchased from Sinopharm Chemical Reagent Co., Ltd. (China). Reaction progress was monitored using analytical thin layer chromatography (TLC) on precoated silica gel GF254 (Qingdao Haiyang Chemical Plant, Qingdao, China) plates and the spots were detected under UV light (254 nm). Melting point was measured on an XT-4 micromelting point instrument and uncorrected. IR (KBr-disc) spectra were recorded by Bruker Tensor 27 spectrometer. <ce:sup loc="pre">1</ce:sup>H NMR and <ce:sup loc="pre">13</ce:sup>C NMR spectra were measured on a Bruker ACF-500 spectrometer at 25 °C and referenced to TMS. Chemical shifts were reported in ppm (<ce:italic>δ</ce:italic>) using the residual solvent line as internal standard. Splitting patterns were designed as s, singlet; d, doublet; t, triplet; m, multiplet. The purity of all compounds used for biological evaluation was confirmed to be higher than 95% through analytical HPLC performed with Agilent 1200 HPLC System. Mass spectra were obtained on a MS Agilent 1100 Series LC/MSD Trap mass spectrometer (ESI-MS) and a Mariner ESI-TOF spectrometer (HRESI-MS), respectively. Column chromatography was performed on silica gel (90–150 μm; Qingdao Marine Chemical Inc).</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title id="sectitle0125">General procedures for the preparation of <ce:bold>2a</ce:bold> and <ce:bold>2b</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0135" view="all">To a stirred solution of compound <ce:bold>1a or 1b</ce:bold>(9.90 mmol)in DMF (20 mL) was added methyl thioglycolate (10.9 mmol) and potassium carbonate (39.6 mmol). The resulting mixture was stirred at 60 °C for 15 h. The DMF was removed under reduced pressure, water (50 mL) was added and the mixture was extracted with ethyl acetate (2 × 40 mL). The combined organic layers were dried with sodium sulfate, filtered, and the solvents were removed under reduced pressure to afford the title compound <ce:bold>2a</ce:bold> or <ce:bold>2b.</ce:bold>
                        </ce:para>
                        <ce:section id="sec4.1.1.1" view="all">
                           <ce:label>4.1.1.1</ce:label>
                           <ce:section-title id="sectitle0130">Methyl 6-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylate (<ce:bold>2a</ce:bold>)</ce:section-title>
                           <ce:para id="p0140" view="all">Yield 92%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.39 (s, 1H, Ar-H), 8.20 (s, 1H, Ar-H), 7.96 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H, Ar-H), 7.63 (dd, <ce:italic>J</ce:italic> = 8.6, 1.7 Hz, 1H, Ar-H), 3.89 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.1.2" view="all">
                           <ce:label>4.1.1.2</ce:label>
                           <ce:section-title id="sectitle0135">Methyl 7-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylate (<ce:bold>2b</ce:bold>)</ce:section-title>
                           <ce:para id="p0145" view="all">Yield 95%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.14 (s, 1H, Ar-H), 7.83 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, Ar-H), 7.60 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar-H), 7.29 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, Ar-H), 3.96 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title id="sectitle0140">General procedures for the preparation of <ce:bold>3a</ce:bold> and <ce:bold>3b</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0150" view="all">The solution of compound <ce:bold>2a</ce:bold> or <ce:bold>2b</ce:bold> (1.1 mmol) in water (10 mL) was stirred and then potassium hydroxide pellets (5.4 mmol) was added, which was refluxed for 3 h. The aqueous layer was then acidified to pH 1 with 1 M hydrochloric acid solution. The aqueous layer was extracted with dichloromethane (3 × 15 mL). The combined organic layers were dried with sodium sulfate, filtered, and the solvents were removed under reduced pressure to afford the title compound <ce:bold>3a</ce:bold> or <ce:bold>3b.</ce:bold>
                        </ce:para>
                        <ce:section id="sec4.1.2.1" view="all">
                           <ce:label>4.1.2.1</ce:label>
                           <ce:section-title id="sectitle0145">6-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylic acid (<ce:bold>3a</ce:bold>)</ce:section-title>
                           <ce:para id="p0155" view="all">Yield 96%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 13.57 (s, 1H, COOH), 8.36 (s, 1H, Ar-H), 8.10 (s, 1H, Ar-H), 7.95 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H, Ar-H), 7.61 (dd, <ce:italic>J</ce:italic> = 8.6, 1.6 Hz, 1H, Ar-H).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.2.2" view="all">
                           <ce:label>4.1.2.2</ce:label>
                           <ce:section-title id="sectitle0150">7-bromobenzo[<ce:italic>b</ce:italic>]thiophene-2-carboxylic acid (<ce:bold>3b</ce:bold>)</ce:section-title>
                           <ce:para id="p0160" view="all">Yield 96%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 13.68 (s, 1H, COOH), 8.26 (s, 1H, Ar-H), 8.05 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, Ar-H), 7.76 (d, <ce:italic>J</ce:italic> = 7.6 Hz, 1H, Ar-H), 7.43 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, Ar-H).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title id="sectitle0155">General procedures for the preparation of <ce:bold>4a</ce:bold> and <ce:bold>4b</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0165" view="all">A mixture <ce:bold>3a</ce:bold> or <ce:bold>4b</ce:bold> (0.5 mmol), Ag<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (0.05 mmol), AcOH (0.025 mmol) in DMSO (1.0 mL) was stirred at 120 °C. After 16 h, the reaction was cooled down to room temperature and quenched with 1 M hydrochloric acid solution (2 mL) and the aqueous phase extracted with ethyl acetate. The combined organic layers were washed with brine and dried sodium sulfate, filtered, and the solvents were removed under reduced pressure to give analytically pure <ce:bold>4a</ce:bold> or <ce:bold>4b</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.3.1" view="all">
                           <ce:label>4.1.3.1</ce:label>
                           <ce:section-title id="sectitle0160">6-bromobenzo[b] thiophene (<ce:bold>4a</ce:bold>)</ce:section-title>
                           <ce:para id="p0170" view="all">Yield 78%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.10 (s, 1H, Ar-H), 7.95 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H, Ar-H), 7.61 (dd, <ce:italic>J</ce:italic> = 8.6, 1.6 Hz, 1H, Ar-H), 7.56 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.30 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.3.2" view="all">
                           <ce:label>4.1.3.2</ce:label>
                           <ce:section-title id="sectitle0165">7-bromobenzo[b] thiophene (<ce:bold>4b</ce:bold>)</ce:section-title>
                           <ce:para id="p0175" view="all">Yield 76%, white solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.06 (s, 1H, Ar-H), 7.96 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, Ar-H), 7.65 (dd, <ce:italic>J</ce:italic> = 8.1, 1.0 Hz, 1H, Ar-H), 7.50–7.46 (m, 2H, Ar-H).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title id="sectitle0170">General procedures for the preparation of <ce:bold>5a</ce:bold> and <ce:bold>5b</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0180" view="all">3-Chloroperbenzoic acid (2.5 mmol) was added to the stirred solution of compound <ce:bold>4a</ce:bold> or <ce:bold>4b</ce:bold> (1.0 mmol) in dichloromethane (50 mL) in portions over a 20–30 min period. The mixture was heated to reflux for about 5 h and monitored by TLC. After completion, the mixture was cooled to room temperature and sodium hydrogen sulfite (20 mL) was added. The solution was stirred for 15 min and extracted with dichloromethane. The organic phase was washed with aqueous sodium bicarbonate (2 × 30 mL). The organic phase was separated, washed with brine and dried with sodium sulfate, filtered, and the solvents were removed under reduced pressure to give the sulfone compound <ce:bold>
                              <ce:italic>5a</ce:italic>
                           </ce:bold> or <ce:bold>
                              <ce:italic>5b</ce:italic>
                           </ce:bold>.</ce:para>
                        <ce:section id="sec4.1.4.1" view="all">
                           <ce:label>4.1.4.1</ce:label>
                           <ce:section-title id="sectitle0175">6-bromobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>5a</ce:bold>)</ce:section-title>
                           <ce:para id="p0185" view="all">Yield 81%, light yellow solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.18 (s, 1H, Ar-H), 7.90 (dd, <ce:italic>J</ce:italic> = 8.0, 1.6 Hz, 1H, Ar-H), 7.63 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H, Ar-H), 7.54 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, Ar-H), 7.40 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H, Ar-H).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.4.2" view="all">
                           <ce:label>4.1.4.2</ce:label>
                           <ce:section-title id="sectitle0180">7-bromobenzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>5b</ce:bold>)</ce:section-title>
                           <ce:para id="p0190" view="all">Yield 81%, light yellow solid; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.78 (m, 1H, Ar-H), 7.59 (m, 3H, Ar-H), 7.44 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H, Ar-H).</ce:para>
                        </ce:section>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title id="sectitle0185">General procedures for the preparation of <ce:bold>6</ce:bold>–<ce:bold>29</ce:bold>
                        </ce:section-title>
                        <ce:para id="p0195" view="all">To a solution of <ce:bold>5a</ce:bold> or <ce:bold>5b</ce:bold> (0.05 mmol) in toluene (10 mL) was added aniline (0.06 mmol), Cs<ce:inf loc="post">2</ce:inf>CO<ce:inf loc="post">3</ce:inf> (0.07 mmol), BINAP (0.004 mmol), and Pd(OAc)<ce:inf loc="post">2</ce:inf> (0.004 mmol) at room temperature. The reaction mixture was allowed to stir at 120 °C for 4–48 h. Once the reaction appeared to be complete by consumption of the bromide by TLC, the mixture was allowed to cool to room temperature, diluted with ethyl acetate, washed with 1 M hydrochloric acid solution, brine, and dried over sodium sulfate. The solution was concentrated, loaded on silica gel, and purified by silica gel chromatography with petroleum/ethyl acetate as eluent to give <ce:bold>6</ce:bold>–<ce:bold>29</ce:bold>.</ce:para>
                        <ce:section id="sec4.1.5.1" view="all">
                           <ce:label>4.1.5.1</ce:label>
                           <ce:section-title id="sectitle0190">6-((3-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>6</ce:bold>)</ce:section-title>
                           <ce:para id="p0200" view="all">Yield 45%, yellow solid; m.p. 118–120 °C; IR (KBr) <ce:italic>ν</ce:italic> 3375, 1601, 1529, 1496, 1412, 1337, 1283, 1206, 1124, 1070, 868, 827, 792, 743, 699, 623 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 7.45 (t, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, Ar-H), 7.38–7.30 (m, 4H, Ar-H), 7.22 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar-H), 7.15 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H, Ar-H), 7.12 (dd, <ce:italic>J</ce:italic> = 8.2, 1.9 Hz, 1H, Ar-H), 6.57 (d, <ce:italic>J</ce:italic> = 6.9 Hz, 1H, Ar-H), 6.24 (s, 1H, NH). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 145.54 (s), 142.36 (s), 138.29 (s), 132.99 (s), 130.62 (s), 128.08 (s), 127.04 (s), 122.06 (s), 121.53 (s), 119.12 (s), 117.67 (s), 114.41 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 3.9 Hz), 108.82 (s). MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0460 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.2" view="all">
                           <ce:label>4.1.5.2</ce:label>
                           <ce:section-title id="sectitle0195">6-((4-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>7</ce:bold>)</ce:section-title>
                           <ce:para id="p0205" view="all">Yield 73%, yellow solid; m.p. 112–114 °C; IR (KBr) <ce:italic>ν</ce:italic> 3375, 1601, 1509, 1496, 1412, 1321, 1283, 1206, 1124, 1070, 868, 792, 743, 699, 559 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 9.25 (s, 1H, NH), 7.63 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar-H), 7.55 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.47 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar-H), 7.42 (s, 1H, Ar-H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.2, 1.9 Hz, 1H, Ar-H), 7.28 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar-H), 7.15 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 145.33, 144.88, 138.20, 132.93, 128.39, 126.98, 126.67 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 3.7 Hz), 124.56 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 270.0 Hz), 122.61, 120.83, 120.221, 117.09, 109.16. MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0460 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.3" view="all">
                           <ce:label>4.1.5.3</ce:label>
                           <ce:section-title id="sectitle0200">3-((1, 1-dioxidobenzo[<ce:italic>b</ce:italic>]thiophen-6-yl) amino) benzonitrile (<ce:bold>8</ce:bold>)</ce:section-title>
                           <ce:para id="p0210" view="all">Yield 43%, yellow solid; m.p. 122–124 °C; IR (KBr) <ce:italic>ν</ce:italic> 3449, 2923, 2852, 1609, 1529, 1262, 1491, 1262, 1188, 1081, 967, 791, 546 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 9.13 (s, 1H, NH), 7.54 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.52–7.49 (m, 2H, Ar-H), 7.45 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar-H), 7.38 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H, Ar-H), 7.32 (dd, <ce:italic>J</ce:italic> = 8.3, 1.9 Hz, 1H, Ar-H), 7.13 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 145.27, 142.45, 138.26, 132.95, 130.73, 128.17, 127.00, 124.82, 122.82, 122.23, 120.62, 119.32, 118.66, 112.28, 109.08. MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0460 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>Cl<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.4" view="all">
                           <ce:label>4.1.5.4</ce:label>
                           <ce:section-title id="sectitle0205">6-((4-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>9</ce:bold>)</ce:section-title>
                           <ce:para id="p0215" view="all">Yield 32%, yellow solid; m.p. 170–172 °C; IR (KBr) <ce:italic>ν</ce:italic> 3345, 1607, 1509, 1496, 1412, 1337, 1276, 1206, 1135, 1032, 821, 742, 684, 597 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.61 (s, 1H, NH), 7.46 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.31 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, Ar-H), 7.13 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 2H, Ar-H), 7.07 (s, 1H, Ar-H), 7.02–6.93 (m, 4H, Ar-H), 3.75 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 155.55, 148.64, 138.44, 133.49, 133.31, 126.89, 126.60, 123.17, 119.39, 116.20, 114.80, 105.97, 55.22. MS (ESI) <ce:italic>m/z</ce:italic> 288.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 288.0688 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 288.0689 C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.5" view="all">
                           <ce:label>4.1.5.5</ce:label>
                           <ce:section-title id="sectitle0210">6-((4-chlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>10</ce:bold>)</ce:section-title>
                           <ce:para id="p0220" view="all">Yield 73%, yellow solid; m.p. 118–120 °C; IR (KBr) <ce:italic>ν</ce:italic> 3421, 2853, 1589, 1521, 1471, 1289, 1201, 1137, 1113, 816, 628, 520 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.94 (s, 1H, NH), 7.51 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.38 (m, 3H, Ar-H), 7.27 (s, 1H, Ar-H), 7.22 (dd, <ce:italic>J</ce:italic> = 8.7, 2.1 Hz, 1H, Ar-H), 7.17 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H, Ar-H), 7.07 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 146.27, 140.18, 138.30, 133.06, 129.25, 127.61, 126.93, 125.37, 121.18, 120.53, 118.22, 107.91. MS (ESI) <ce:italic>m/z</ce:italic> 292.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 292.0192 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 292.0194 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>ClNO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.6" view="all">
                           <ce:label>4.1.5.6</ce:label>
                           <ce:section-title id="sectitle0215">6-((3, 4-dichlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>11</ce:bold>)</ce:section-title>
                           <ce:para id="p0225" view="all">Yield 45%, yellow solid; m.p. 165–167 °C; IR (KBr) <ce:italic>ν</ce:italic> 3421, 2924, 2853, 1589, 1521, 1471, 1276, 1201, 1137, 1023, 816, 628, 531 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 9.07 (s, 1H, NH), 7.53 (d, <ce:italic>J</ce:italic> = 7.4 Hz, 2H, Ar-H), 7.44 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 1H, Ar-H), 7.34–7.31 (m, 3H, Ar-H), 7.23–7.08 (m, 2H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 145.28, 141.83, 138.24, 132.93, 131.59, 131.12, 128.16, 127.00, 122.59, 122.20, 119.40, 118.25, 109.04. MS (ESI) <ce:italic>m/z</ce:italic> 281.0 [M+H] <ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 281.0390 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 281.0390 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">9</ce:inf>Cl<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.7" view="all">
                           <ce:label>4.1.5.7</ce:label>
                           <ce:section-title id="sectitle0220">6-((3, 4-difluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>12</ce:bold>)</ce:section-title>
                           <ce:para id="p0230" view="all">Yield 44%, yellow solid; m.p. 132–134 °C; IR (KBr) <ce:italic>ν</ce:italic> 3370, 2923, 2852, 1601, 1571, 1510, 1407, 1366, 1292, 1265, 1162, 1137, 1061, 1029, 962, 824, 746, 622, 600, 561 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.93 (s, 1H, NH), 7.51 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.38 (dd, <ce:italic>J</ce:italic> = 18.0, 8.7 Hz, 2H, Ar-H), 7.27 (d, <ce:italic>J</ce:italic> = 1.6 Hz, 1H, Ar-H), 7.24–7.14 (m, 2H, Ar-H), 7.08 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.01–6.93 (m, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.68 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 245.0 Hz), 146.33, 144.39 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 245.0 Hz), 138.45 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 8.5 Hz), 138.32, 133.06, 127.74, 127.00, 121.39, 118.20, 118.03 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 18.0 Hz), 115.68 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 5.9 Hz), 108.28 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 19.4 Hz), 108.02. MS (ESI) <ce:italic>m/z</ce:italic> 294.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 294.0397 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 294.0395 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>F<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.8" view="all">
                           <ce:label>4.1.5.8</ce:label>
                           <ce:section-title id="sectitle0225">7-((3, 4, 5-trimethoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>13</ce:bold>)</ce:section-title>
                           <ce:para id="p0235" view="all">Yield 56%, yellow solid; m.p. 166–167 °C; IR (KBr) <ce:italic>ν</ce:italic> 3348, 2923, 1585, 1505, 1472, 1427, 1393, 1314, 1279, 1127, 1000, 964, 836, 790, 728, 683, 649, 600, 549 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.74 (s, 1H, NH), 7.49 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.35 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, Ar-H), 7.20 (d, <ce:italic>J</ce:italic> = 10.3 Hz, 2H, Ar-H), 7.03 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 6.45 (s, 2H, Ar-H), 3.76 (s, 6H, OCH<ce:inf loc="post">3</ce:inf>), 3.66 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 153.40, 153.23, 147.42, 138.34, 136.90, 133.24 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 19.8 Hz), 127.10, 126.91, 120.21, 117.31, 107.53, 98.16, 91.82, 60.07, 55.80, 55.36. MS (ESI) <ce:italic>m/z</ce:italic> 348.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 348.0902 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 348.0900, C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">5</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.9" view="all">
                           <ce:label>4.1.5.9</ce:label>
                           <ce:section-title id="sectitle0230">6-((3-(trifluoromethoxy) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>14</ce:bold>)</ce:section-title>
                           <ce:para id="p0240" view="all">Yield 34%, yellow solid; m.p. 132–134 °C; IR (KBr) <ce:italic>ν</ce:italic> 3372, 3098, 2924, 1599, 1526, 1494, 1408, 1327, 1250, 1210, 850, 829, 797, 744, 726, 682, 627, 527 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 9.10 (s, 1H, NH), 7.53 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.44 (dt, <ce:italic>J</ce:italic> = 8.1, 4.0 Hz, 2H, Ar-H), 7.33 (s, 1H, Ar-H), 7.29 (dd, <ce:italic>J</ce:italic> = 8.2, 1.9 Hz, 1H, Ar-H), 7.18 (d, <ce:italic>J</ce:italic> = 8.1 Hz, 1H, Ar-H), 7.12 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.05 (s, 1H, Ar-H), 6.93 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.22, 145.52, 143.32, 138.26, 132.97, 131.09, 128.06, 127.00, 121.99, 119.18, 116.78, 113.31, 110.31, 108.75. MS (ESI) <ce:italic>m/z</ce:italic> 342.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 342.0407 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 342.0406 C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.10" view="all">
                           <ce:label>4.1.5.10</ce:label>
                           <ce:section-title id="sectitle0235">7-((3-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>15</ce:bold>)</ce:section-title>
                           <ce:para id="p0245" view="all">Yield 55%, yellow solid; m.p. 120–122 °C; IR (KBr) <ce:italic>ν</ce:italic> 3335, 2920, 2851, 1611, 1587, 1562, 1524, 1494, 1394, 1332, 1281, 1223, 1169, 1136, 1113, 1076, 895, 795, 717, 698, 682, 660, 642, 600, 551 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.39 (s, 1H, NH), 7.55 (t, <ce:italic>J</ce:italic> = 5.0 Hz, 1H, Ar-H), 7.54–7.45 (m, 3H, Ar-H), 7.41 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, Ar-H), 7.31 (dd, <ce:italic>J</ce:italic> = 12.2, 7.6 Hz, 2H, Ar-H), 7.26 (d, <ce:italic>J</ce:italic> = 7.5 Hz, 1H, Ar-H), 7.12 (m, 1H, Ar-H). MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0455 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457, C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">2</ce:inf>S). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 143.29, 138.55, 135.09, 133.33, 132.26, 131.61, 130.10, 129.83, 125.15, 124.20 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 245.0 Hz), 122.99, 121.99, 119.18, 117.59, 115.22 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 3.8 Hz).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.11" view="all">
                           <ce:label>4.1.5.11</ce:label>
                           <ce:section-title id="sectitle0240">7-((4-(trifluoromethoxy) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>16</ce:bold>)</ce:section-title>
                           <ce:para id="p0250" view="all">Yield 55%, yellow solid; m.p. 108–110 °C; IR (KBr) <ce:italic>ν</ce:italic> 3343, 1590, 1516, 1470, 1270, 851, 786, 677, 613, 557, 521 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 9.25 (s, 1H, NH), 7.63 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar-H), 7.55 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.47 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar-H), 7.42 (s, 1H, Ar-H), 7.38 (dd, <ce:italic>J</ce:italic> = 8.2, 1.9 Hz, 1H, Ar-H), 7.28 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 2H, Ar-H), 7.15 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 142.84, 141.15, 139.39, 134.97, 133.22, 132.33, 131.52, 122.71, 121.96, 121.05, 120.86, 118.22. MS (ESI) <ce:italic>m/z</ce:italic> 342.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 342.0405 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 342.0406, C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.12" view="all">
                           <ce:label>4.1.5.12</ce:label>
                           <ce:section-title id="sectitle0245">7-((3, 4, 5-trimethoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>17</ce:bold>)</ce:section-title>
                           <ce:para id="p0255" view="all">Yield 60%, yellow solid; m.p. 168–170 °C; IR (KBr) <ce:italic>ν</ce:italic> 3348, 2923, 1585, 1505, 1472, 1427, 1393, 1314, 1279, 1233, 1180, 1127, 1000, 964, 836, 790, 728, 683, 649, 600, 549 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.76 (s, 1H, NH), 7.50 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.45–7.37 (m, 1H, Ar-H), 7.29–7.22 (m, 2H, Ar-H), 6.93 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H, Ar-H), 6.57 (s, 2H, Ar-H), 3.73 (s, 6H, OCH<ce:inf loc="post">3</ce:inf>), 3.64 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 153.16, 140.31, 136.66, 134.85, 133.45, 133.06, 132.46, 131.35, 120.31, 119.23, 116.73, 99.05, 60.05, 55.77, 39.52, 39.35, 39.19, 39.02. MS (ESI) <ce:italic>m/z</ce:italic> 348.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 348.0901 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 348.0900, C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">18</ce:inf>NO<ce:inf loc="post">5</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.13" view="all">
                           <ce:label>4.1.5.13</ce:label>
                           <ce:section-title id="sectitle0250">7-((4-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>18</ce:bold>)</ce:section-title>
                           <ce:para id="p0260" view="all">Yield 73%, yellow solid; m.p. 166–168 °C; IR (KBr) <ce:italic>ν</ce:italic> 3356, 2923, 1608, 1532, 1471, 1323, 1292, 1294, 1162, 1144, 1107, 1065, 795, 678, 619, 555, 520 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.49 (s, 1H, NH), 7.57 (d, <ce:italic>J</ce:italic> = 7.0 Hz, 4H, Ar-H), 7.41 (d, <ce:italic>J</ce:italic> = 8.0 Hz, 1H, Ar-H), 7.34–7.29 (m, 1H Ar-H), 7.24 (d, <ce:italic>J</ce:italic> = 7.9 Hz, 2H Ar-H), 7.20 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 146.79, 137.88, 135.16, 133.35, 132.29, 131.69, 126.33 (d, <ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 3.7 Hz), 125.80, 123.89, 120.19, 117.32. MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0455 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457, C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">11</ce:inf>F<ce:inf loc="post">3</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.14" view="all">
                           <ce:label>4.1.5.14</ce:label>
                           <ce:section-title id="sectitle0255">7-((4-chlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>19</ce:bold>)</ce:section-title>
                           <ce:para id="p0265" view="all">Yield 56%, yellow solid; m.p. 120–122 °C; IR (KBr) <ce:italic>ν</ce:italic> 3347, 3096, 1598, 1598, 1517, 1491, 1468, 1352, 1321, 1295, 1215, 1170, 1135, 1092, 1009, 812, 791, 728, 698, 621, 599, 555, 520 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.11 (s, 1H, NH), 7.52 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.48–7.42 (m, 1H, Ar-H), 7.33 (d, <ce:italic>J</ce:italic> = 8.7 Hz, 2H, Ar-H), 7.28 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.23–7.19 (m, 3H, Ar-H), 7.03 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 140.75, 139.48, 134.96, 133.24, 132.38, 131.52, 128.94, 125.77, 122.38, 121.68, 120.61, 118.03. MS (ESI) <ce:italic>m/z</ce:italic> 292.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 292.0192 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 292.0194, C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>ClNO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.15" view="all">
                           <ce:label>4.1.5.15</ce:label>
                           <ce:section-title id="sectitle0260">7-((3, 5-dimethylphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>20</ce:bold>)</ce:section-title>
                           <ce:para id="p0270" view="all">Yield 45%, yellow solid; m.p. >250 °C; IR (KBr) <ce:italic>ν</ce:italic> 3346, 2919, 1587, 1519, 1469, 1333, 1283, 1216, 1135, 1032, 857, 838, 786, 680, 649, 621, 601, 551 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.67 (s, 1H, NH), 7.50 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.44–7.39 (m, 1H, Ar-H), 7.26 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.18 (d, <ce:italic>J</ce:italic> = 8.4 Hz, 1H, Ar-H), 6.95 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 6.83 (s, 2H, Ar-H), 6.68 (s, 1H, Ar-H), 2.23 (s, 6H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 140.87, 138.27, 134.81, 132.47, 131.39, 124.43, 119.75, 118.49, 116.99, 40.02, 39.52, 39.35, 39.19, 39.02, 20.93. MS (ESI) <ce:italic>m/z</ce:italic> 286.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 286.0895 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 286.0896, C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">16</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.16" view="all">
                           <ce:label>4.1.5.16</ce:label>
                           <ce:section-title id="sectitle0265">7-((Perfluorophenyl) amino)benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>21</ce:bold>)</ce:section-title>
                           <ce:para id="p0275" view="all">Yield 56%, yellow solid; m.p. 189–191 °C; IR (KBr) <ce:italic>ν</ce:italic> 3397, 3081, 2922, 1612, 1568, 1512, 1368, 1288, 1182, 1133, 1088, 1034, 986, 843, 790, 738, 701, 652, 589, 534 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.37 (s, 1H, NH), 7.49 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.49–7.41 (m, 1H, Ar-H), 7.21 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 6.96 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H), 6.90 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 140.94, 135.02, 133.19, 132.54, 131.10, 119.09, 118.88, 117.09. MS (ESI) <ce:italic>m/z</ce:italic> 346.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 345.9968 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 345.9967, C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">6</ce:inf>NF<ce:inf loc="post">5</ce:inf>O<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.17" view="all">
                           <ce:label>4.1.5.17</ce:label>
                           <ce:section-title id="sectitle0270">7-((3-Fluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>22</ce:bold>)</ce:section-title>
                           <ce:para id="p0280" view="all">Yield 56%, yellow solid; m.p. 143–145 °C; IR (KBr) <ce:italic>ν</ce:italic> 3396, 2923, 2852, 1605, 1467, 1261, 1098, 801, 681, 633, 548, 520 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.18 (s, 1H, NH), 7.54 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.52–7.46 (m, 1H, Ar-H), 7.36–7.31 (m, 1H, Ar-H), 7.31–7.28 (m, 2H), 7.09 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H), 7.02–6.94 (m, 2H, Ar-H), 6.76 (td, <ce:italic>J</ce:italic> = 8.5, 2.3 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 144.17 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 10.8 Hz), 138.86, 134.97, 133.21, 132.31, 131.54, 130.54 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 9.8 Hz), 121.78, 118.76, 114.76, 108.12, 107.95, 105.99, 105.79. MS (ESI) <ce:italic>m/z</ce:italic> 276.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 276.0490 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 276.0489, C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>FNO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.18" view="all">
                           <ce:label>4.1.5.18</ce:label>
                           <ce:section-title id="sectitle0275">7-(p-tolylamino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>23</ce:bold>)</ce:section-title>
                           <ce:para id="p0285" view="all">Yield 45%, yellow solid; m.p. >250 °C; IR (KBr) <ce:italic>ν</ce:italic> 3376, 3350, 2921, 2851, 1596, 1519, 1473, 1331, 1288, 1262, 1156, 1128, 1097, 816, 777, 627, 548, 491 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.79 (s, 1H, NH), 7.49 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.40–7.34 (m, 1H, Ar-H), 7.25 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.15–7.11 (m, 4H, Ar-H), 7.08 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H, Ar-H), 6.90 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H, Ar-H), 2.28 (s, 3H, CH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 140.74, 138.07, 134.74, 133.05, 132.46, 132.29, 131.34, 129.61, 121.83, 118.55, 119.91, 116.39, 20.35. MS (ESI) <ce:italic>m/z</ce:italic> 272.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 272.0741 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 272.0740 C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.19" view="all">
                           <ce:label>4.1.5.19</ce:label>
                           <ce:section-title id="sectitle0280">7-((4-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>24</ce:bold>)</ce:section-title>
                           <ce:para id="p0290" view="all">Yield 68%, yellow solid; m.p. 142–144 °C; IR (KBr) <ce:italic>ν</ce:italic> 3444, 3335, 3085, 2929, 2852, 1612, 1512, 1468, 1395, 1354, 1321, 1284, 1258, 1138, 1084, 1036, 846, 823, 788, 721, 683, 640, 607, 555, 505 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.74 (s, 1H, NH), 7.47 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.35–7.30 (m, 1H, Ar-H), 7.23 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.17 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 2H, Ar-H), 6.94 (t, <ce:italic>J</ce:italic> = 6.1 Hz, 2H, Ar-H), 6.91 (d, <ce:italic>J</ce:italic> = 8.5 Hz, 1H, Ar-H), 6.83 (d, <ce:italic>J</ce:italic> = 7.1 Hz, 1H, Ar-H), 3.75 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 156.05, 141.66, 134.71, 133.02, 132.48, 131.29, 124.88, 118.50, 117.41, 115.50, 114.91, 114.49, 55.21. MS (ESI) <ce:italic>m/z</ce:italic> 288.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 288.0688 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 288.0689 C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.20" view="all">
                           <ce:label>4.1.5.20</ce:label>
                           <ce:section-title id="sectitle0285">7-((2-Methoxyphenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>25</ce:bold>)</ce:section-title>
                           <ce:para id="p0295" view="all">Yield 53%, yellow solid; m.p. 116–118 °C; 3393, 2923, 2852, 1589, 1518, 1463, 1286, 1136, 1024, 797, 747, 631, 526 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.54 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.46–7.41 (m, 1H, Ar-H), 7.31 (t, <ce:italic>J</ce:italic> = 7.2 Hz, 2H, Ar-H), 7.15–7.06 (m, 4H, Ar-H), 6.96 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 3.83 (s, 3H, OCH<ce:inf loc="post">3</ce:inf>). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 150.42, 139.72, 134.98, 132.91, 132.69, 131.16, 128.55, 123.98, 120.68, 120.12, 119.72, 117.75, 116.74, 111.85, 55.78. MS (ESI) <ce:italic>m/z</ce:italic> 288.1 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 288.0687 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 288.0689 C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">14</ce:inf>NO<ce:inf loc="post">3</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.21" view="all">
                           <ce:label>4.1.5.21</ce:label>
                           <ce:section-title id="sectitle0290">7-((3, 4-difluorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>26</ce:bold>)</ce:section-title>
                           <ce:para id="p0300" view="all">Yield 53%, yellow solid; m.p. 176–177 °C; 3444, 3350, 1608, 1560, 1514, 1464, 1386, 1355, 1277, 1202, 1172, 1138, 1103, 1078, 946, 855, 840, 791, 709, 687, 687, 633, 598, 572, 546, 515, 484, 445 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.15 (s, 1H, NH), 7.53 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.46 (t, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, Ar-H), 7.36–7.32 (m, 1H, Ar-H), 7.28 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.26–7.19 (m, 2H, Ar-H), 7.04 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H), 7.00 (d, <ce:italic>J</ce:italic> = 8.6 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 149.48 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 244.1 Hz), 144.95 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 239.9 Hz), 139.42, 138.99 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 8.7 Hz), 135.02, 133.22, 132.35, 131.51, 122.45, 120.62, 118.18, 117.58 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 17.7 Hz), 116.40 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 5.9 Hz), 109.36 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 19.7 Hz). MS (ESI) <ce:italic>m/z</ce:italic> 294.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 294.0393 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 294.0395 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>F<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.22" view="all">
                           <ce:label>4.1.5.22</ce:label>
                           <ce:section-title id="sectitle0295">7-((3, 4-dichlorophenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>27</ce:bold>)</ce:section-title>
                           <ce:para id="p0305" view="all">Yield 66%, yellow solid; m.p. 165–167 °C; 3354, 1590, 1504, 1466, 1375, 1318, 1286, 1138, 862, 798, 686, 625, 556, 520 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.34 (s, 1H, NH), 7.55 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.54–7.49 (m, 1H, Ar-H), 7.47 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H, Ar-H), 7.35 (d, <ce:italic>J</ce:italic> = 2.6 Hz, 1H, Ar-H), 7.33 (d, <ce:italic>J</ce:italic> = 8.3 Hz, 1H, Ar-H), 7.30 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.14 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H), 7.11 (dd, <ce:italic>J</ce:italic> = 8.8, 2.6 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 147.28, 140.80, 138.24, 132.93, 131.59, 131.12, 128.16, 127.00, 122.59, 122.20, 119.40, 118.25, 109.04. MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 325.9803 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 325.9804 C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">10</ce:inf>Cl<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.23" view="all">
                           <ce:label>4.1.5.23</ce:label>
                           <ce:section-title id="sectitle0300">7-((3, 5-bis (trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>28</ce:bold>)</ce:section-title>
                           <ce:para id="p0310" view="all">Yield 70%, yellow solid; m.p. 202–204 °C; 3366, 2921, 2850, 1601, 1539, 1476, 1384, 1278, 1218, 1182, 1166, 1144, 1119, 931, 892, 878, 836, 801, 719, 705, 682, 642, 552, 522, 484 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 8.87 (s, 1H, NH), 7.66–7.58 (m, 4H, Ar-H), 7.49 (s, 1H, Ar-H), 7.46 (d, <ce:italic>J</ce:italic> = 8.2 Hz, 1H, Ar-H), 7.34 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.28 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 145.53, 136.83, 135.54, 133.49, 132.24, 131.72, 131.08 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 32.6 Hz), 124.27 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 13.2 Hz), 122.15, 121.16, 116.67, 112.74. MS (ESI) <ce:italic>m/z</ce:italic> 394.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 394.0332 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 390.0331 C<ce:inf loc="post">16</ce:inf>H<ce:inf loc="post">9</ce:inf>F<ce:inf loc="post">6</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                        <ce:section id="sec4.1.5.24" view="all">
                           <ce:label>4.1.5.24</ce:label>
                           <ce:section-title id="sectitle0305">7-((2-(trifluoromethyl) phenyl) amino) benzo[<ce:italic>b</ce:italic>]thiophene 1, 1-dioxide (<ce:bold>29</ce:bold>)</ce:section-title>
                           <ce:para id="p0315" view="all">Yield 76%, yellow solid; m.p. 125–127 °C; 3412, 3087, 2922, 2851, 1599, 1556, 1522, 1468, 1326, 1281, 1219, 1143, 1113, 1036, 855, 793, 761, 687, 651, 631, 596, 551, 526 cm<ce:sup loc="post">−1</ce:sup>; <ce:sup loc="pre">1</ce:sup>H NMR (500 MHz, DMSO) <ce:italic>δ</ce:italic> 7.77 (d, <ce:italic>J</ce:italic> = 7.8 Hz, 1H, Ar-H), 7.68 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, Ar-H), 7.56 (d, <ce:italic>J</ce:italic> = 6.8 Hz, 1H, Ar-H), 7.47 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H, Ar-H), 7.43 (d, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, Ar-H), 7.37 (t, <ce:italic>J</ce:italic> = 7.7 Hz, 1H, Ar-H), 7.32 (m, 2H, NH, Ar-H), 7.02 (d, <ce:italic>J</ce:italic> = 7.2 Hz, 1H, Ar-H), 6.93 (d, <ce:italic>J</ce:italic> = 8.8 Hz, 1H, Ar-H). <ce:sup loc="pre">13</ce:sup>C NMR (126 MHz, DMSO) <ce:italic>δ</ce:italic> 139.76, 138.33, 135.11, 133.79, 132.86, 132.80, 131.32, 127.01 (<ce:italic>J</ce:italic>
                              <ce:inf loc="post">
                                 <ce:italic>CF</ce:italic>
                              </ce:inf> = 5.2 Hz), 125.02, 124.69, 120.75, 118.96, 117.63. MS (ESI) <ce:italic>m/z</ce:italic> 326.0 [M+H]<ce:sup loc="post">+</ce:sup>; HRMS (ESI) <ce:italic>m/z</ce:italic> 326.0458 [M+H]<ce:sup loc="post">+</ce:sup> (calcd for 326.0457 C<ce:inf loc="post">14</ce:inf>H10Cl<ce:inf loc="post">2</ce:inf>NO<ce:inf loc="post">2</ce:inf>S).</ce:para>
                        </ce:section>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title id="sectitle0310">Docking</ce:section-title>
                     <ce:para id="p0320" view="all">Computational docking program AutoDock4.2 was used to dock our designed small molecules to predict their binding modes and approximate binding free energies to the STAT3 SH2 dimerization sites <ce:cross-ref refid="bib5" id="crosref0170">[5]</ce:cross-ref>. Briefly, compounds were docked using the Lamarckian Genetic Algorithm. The ligand and macromolecule were prepared using the Schrödinger software. Gasteiger charges were assigned to the ligands by Auto Dock Tools. Then, AutoGrid maps were precomputed for all atom types in the ligand set. After 10 million energy evaluations were completed, the root-mean-square deviation threshold was set as 1.5 Å and all the resulting conformations of the ligands in the binding pocket of the macromolecule were clustered. Low energy clusters were identified and binding energies were evaluated.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.3" view="all">
                     <ce:label>4.3</ce:label>
                     <ce:section-title id="sectitle0315">Maintenance of cell lines culture and cell viability assays</ce:section-title>
                     <ce:para id="p0325" view="all">All cell lines were purchased from Cell Bank of Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences (Shanghai, China). Human non-small cell lung carcinoma cell (A549), human breast carcinoma cell (MCF-7) and (MDA-MB-231), human colon carcinoma cell (HCT116) were maintained in RPMI-1640 medium. All cells were supplemented with 10% fetal bovine serum containing 50 μg/ml penicillin and 50 μg/ml streptomycin. Cells were grown to 80% confluency in a tissue culture flask at 37 °C in a humidified atmosphere containing 5% CO<ce:inf loc="post">2</ce:inf>, and then were trypsinized with 1 × Trypsin-Versene and splitted.</ce:para>
                     <ce:para id="p0330" view="all">Cells (MDA-MB-231, A549, MCF-7, HCT116) were seeded in 96-well plates at a density of 3000–5000 cells per well. The cells were incubated at 37 °C overnight (16 h) in a humidified 5% CO<ce:inf loc="post">2</ce:inf> incubator. After medium removal, different concentrations of test compounds were added in triplicate to the plates in 200 μL fresh mediums, the plates were incubated at 37 °C for 72 h. The percentage of DMSO in the medium not exceeded 0.1%. 3-(4, 5-Dimethylthiazolyl)-2, 5-diphenyltetrazoliumbromide (MTT) was added to evaluate cell viability. The absorbance was read by an ELISA reader (SpectraMax Plus384, Molecular Devices, Sunnyvale, CA) at a test wavelength of 570 nm and a reference wavelength of 630 nm. Cell viability was calculated by the following formula:<ce:display>
                           <ce:formula id="ufd1">
                              <ce:chem>% Cell viability = (At/As) × 100%</ce:chem>
                           </ce:formula>
                        </ce:display>
                     </ce:para>
                     <ce:para id="p0335" view="all">At and As denoted the absorbance of the test substances and solvent control, respectively.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.4" view="all">
                     <ce:label>4.4</ce:label>
                     <ce:section-title id="sectitle0320">Western blot analysis</ce:section-title>
                     <ce:para id="p0340" view="all">MDA-MB-231 cells were incubated with various concentrations of <ce:bold>15</ce:bold> for 24 h. Harvesting after trypsinisation, cells were treated with 1 × RIPA lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.25% deoxycholic acid, 1% NP-40, 1 mM EDTA and protease inhibitors) (Amresco, Solon, USA) to extract the total proteins. An aliquot of proteins from the total cell lysates (30–60μg/lane) was separated by sodium dodecyl sulfate (10%) polyacryl amide gel electrophoresis (SDS–PAGE, BioRad Laboratories, Hercules, CA), wet-transferred to NC membrane (BioRad Laboratories, Hercules, CA) and blotted with primary antibodies specific for STAT3, p-STAT3, p-Jak2, Jak2, p-Src, Src, Erk, P-Erk, Cleaved Caspase-3, Caspase-3, PARP, Cleaved PARP, Bcl-2 and GAPDH. Bound immuno-complexes were detected using ChemiDOC™ XRS + system (BioRad Laboratories, Hercules, CA).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.5" view="all">
                     <ce:label>4.5</ce:label>
                     <ce:section-title id="sectitle0325">IL-6 induction of STAT3 phosphorylation</ce:section-title>
                     <ce:para id="p0345" view="all">MDA-MB-231 cells were seeded in 6-well plates and allowed to adhere overnight. The following day, the cells were serum-starved. The cells were then left untreated or were treated with <ce:bold>15</ce:bold> (1–5 μM). After 12 h, the untreated and <ce:bold>15</ce:bold> treated cells were stimulated by IL-6 (25 ng/mL). The cells were harvested after 30 min and analyzed by western blot assay.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.6" view="all">
                     <ce:label>4.6</ce:label>
                     <ce:section-title id="sectitle0330">Electrophoretic mobility shift assay (EMSA) of DNA-binding activity</ce:section-title>
                     <ce:para id="p0350" view="all">MDA-MB-231 cells were cultured in culture dish overnight and then treated with compound <ce:bold>15</ce:bold> in fresh regular growth medium for 24 h. The cells were harvested and nuclear extract preparations and EMSA analysis were carried out as previously described <ce:cross-ref refid="bib10" id="crosref0175">[10]</ce:cross-ref>. The <ce:sup loc="pre">32</ce:sup>P labeled oligonucleotide hSIE probe was used to bind STAT3.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.7" view="all">
                     <ce:label>4.7</ce:label>
                     <ce:section-title id="sectitle0335">Flow cytometry analysis of apoptotic cells</ce:section-title>
                     <ce:para id="p0355" view="all">MDA-MB-231 cells at a density of 2.5 × 10<ce:sup loc="post">5</ce:sup> per well were cultured in regular growth medium in 6-well plates for 24 h and treated in duplicate with different concentrations of <ce:bold>15</ce:bold> for 24 h. The cells were harvested, washed and stained with 5 μL Annexin V-FITC and 5 μL propidium iodide at room temperature for 15 min. Cells were then analyzed by flow cytometry (488 nm excitation and 600 nm emission filters) using BD FACSCalibur flowcytometer (Becton & Dickinson Company, Franklin Lakes, NJ).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.8" view="all">
                     <ce:label>4.8</ce:label>
                     <ce:section-title id="sectitle0340">ROS detection by flow cytometry</ce:section-title>
                     <ce:para id="p0360" view="all">MDA-MB-231 cells were seeded at a density of 3 × 10<ce:sup loc="post">5</ce:sup> per well of 6-well plates. The cells were treated with various concentrations of <ce:bold>15</ce:bold> (0, 1, 3, 5 μM) for 24 h. DCFH-DA was dissolved in Serum-free medium and diluted to a final concentration of 10 μM. After treatment with <ce:bold>15</ce:bold>, the growth media was replaced with Serum-free medium containing the probe. After incubation for 20 min at 37 °C, cells were washed with Serum-free medium twice, digested by trypsin and resuspended in the pre-warmed PBS buffer. The samples were then subjected to a flow cytometry assay using BD FACSCalibur flowcytometer (Becton & Dickinson Company, Franklin Lakes, NJ).</ce:para>
                  </ce:section>
                  <ce:section id="sec4.9" view="all">
                     <ce:label>4.9</ce:label>
                     <ce:section-title id="sectitle0345">Colony survival assay</ce:section-title>
                     <ce:para id="p0365" view="all">MDA-MB-231 cells were cultured 800–1000 per well in 6-well plate with regular growth medium. Cells were treated by vehicle and <ce:bold>15</ce:bold> at 0.5–6 μM on the following day for 24 h. Cells were allowed to grow for 10–14 d until the colonies were visible. Crystal violet solution (Sigma, St. Louis, MO, USA) was used to stain the colonies for 4 h and colonies were scored manually as described previously <ce:cross-ref refid="bib39" id="crosref0180">[39]</ce:cross-ref>.</ce:para>
                  </ce:section>
                  <ce:section id="sec4.10" view="all">
                     <ce:label>4.10</ce:label>
                     <ce:section-title id="sectitle0350">In vivo studies</ce:section-title>
                     <ce:para id="p0370" view="all">Mouse breast tumor 4T1 inoculation (2 × 10<ce:sup loc="post">6</ce:sup> cells at right armpit) was performed on 5-week old ICR male mice. Twenty-four hours after inoculation, the mice were divided randomly into three groups (6 mice/group) and intraperitoneally administered with <ce:bold>15</ce:bold> 10 mg/kg daily, Doxorubicin 1 mg/kg every four days, respectively. Body weight was measured daily. On the 12th day, all mice were killed, and the tumor was segregated, weighed, and stored in −80 °C for later use. Tumor inhibitory ratio TI (%) was calculated as TI (%) = (1 −W<ce:inf loc="post">T</ce:inf>/W<ce:inf loc="post">C</ce:inf>) × 100, where W<ce:inf loc="post">T</ce:inf> and W<ce:inf loc="post">C</ce:inf> were the average tumor weights of the treated and control group. Body weight inhibitory ratio BI (%) was calculated as BI (%) = (1 −M<ce:inf loc="post">T</ce:inf>/M<ce:inf loc="post">C</ce:inf>) × 100, where M<ce:inf loc="post">T</ce:inf> and M<ce:inf loc="post">C</ce:inf> were the average body weights of the treated and control group, respectively. The levels of p-STAT3 and STAT3 in tumor tissues prepared from control or mice treated with DOX or compound <ce:bold>15</ce:bold> were analyzed by western blot assay.</ce:para>
                     <ce:para id="p0375" view="all">The experimental mice were cared and handled strictly according to obligations of the Animal Ethics Committee of China Pharmaceutical University and the National Institutes of Health (NIH) standard guidelines for the Care and Use of Laboratory Animal.</ce:para>
                  </ce:section>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0355">Acknowledgments</ce:section-title>
               <ce:para id="p0380" view="all">This research work was supported by <ce:grant-sponsor id="gs1" sponsor-id="http://dx.doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs1">81402791</ce:grant-number> and No. <ce:grant-number refid="gs1">81673298</ce:grant-number>), <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Natural Science Foundation of the Jiangsu Higher Education Institutions of China</ce:grant-sponsor> (Grant No. <ce:grant-number refid="gs2">BK20140670</ce:grant-number>), <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Program for Changjiang Scholars and Innovative Research Team in University</ce:grant-sponsor> (<ce:grant-number refid="gs3">IRT_15R63</ce:grant-number>), Project Funded by the <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)</ce:grant-sponsor>.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0360">Supplementary data</ce:section-title>
                  <ce:para id="p0385" view="all">The following is the supplementary data related to this article:<ce:display>
                        <ce:e-component id="ec1">
                           <ce:link locator="mmc1" xlink:type="simple" xlink:href="pii:S0223523416308042/mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title id="sectitle0365">Supplementary data</ce:section-title>
                  <ce:para id="p0390" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2016.09.068" id="intref0015" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2016.09.068</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0370">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs and gene regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1630</sb:first-page>
                              <sb:last-page>1635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Avadisian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115</sb:first-page>
                              <sb:last-page>127</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 inhibitors: a patent review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1159</sb:first-page>
                              <sb:last-page>1168</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Wenying</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Hui</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Jiayuh</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Chenglong</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of novel STAT3 small molecule inhibitors via in silico site-directed fragment-based drug design</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4402</sb:first-page>
                              <sb:last-page>4412</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Escobar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Bjartell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Canesin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Evans-Axelsson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Sterner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Hellsten</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Johansson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical characterization of 3β-(N-Acetyl L-cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a prodrug of a direct STAT3 inhibitor for the treatment of prostate Cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4551</sb:first-page>
                              <sb:last-page>4562</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.W.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Teng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mehndiratta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Liou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>N-Sulfonyl-aminobiaryls as antitubulin agents and inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Signal. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>58</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6549</sb:first-page>
                              <sb:last-page>6558</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Avadisian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Anticancer Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>115</sb:first-page>
                              <sb:last-page>127</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 inhibitors: a patent review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STATs in transcriptional control and their impact on cellular function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2468</sb:first-page>
                              <sb:last-page>2473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Drewry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Shahani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>87</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>825</sb:first-page>
                              <sb:last-page>833</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Brent D.G.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Danielle C.</ce:given-name>
                                 <ce:surname>Croucher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Zhi Hua</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Sina</ce:given-name>
                                 <ce:surname>Haftchenary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Victor H.</ce:given-name>
                                 <ce:surname>Jimenez-Zepeda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Jennifer</ce:given-name>
                                 <ce:surname>Atkinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Paul A.</ce:given-name>
                                 <ce:surname>Spagnuolo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Lim Wong</ce:given-name>
                                 <ce:surname>Yoong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Robert</ce:given-name>
                                 <ce:surname>Colaguori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Andrew M.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Aaron D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Trudel</ce:given-name>
                                 <ce:surname>Suzanne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Patrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting aberrant signal transducer and activator of transcription protein activation with tetrapodal, small molecule Src homology 2 domain binders: promising agents against multiple myeloma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>56</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7190</sb:first-page>
                              <sb:last-page>7200</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Fletcher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharmeen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Schimmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Trudel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Antagonism of the Stat3-Stat3 protein dimer with salicylic acid based small molecules</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1459</sb:first-page>
                              <sb:last-page>1470</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer-new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Validating Stat3 in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Blaskovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>McLaughlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7391</sb:first-page>
                              <sb:last-page>7396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Glenn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Katt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schrock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>787</sb:first-page>
                              <sb:last-page>798</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Tweardy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>279</sb:first-page>
                              <sb:last-page>286</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Weerasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.E.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yuan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Feng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jing</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>136</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Stark</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Benson</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Deangelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Bakan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A small molecule, LLL12 inhibits constitutive STAT3 and IL-6-induced STAT3 signaling and exhibits potent growth suppressive activity in human multiple myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>130</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1459</sb:first-page>
                              <sb:last-page>1469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Hutzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>DeAngelis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Foust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sobo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Friedman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bhasin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel small molecule, LLL12, inhibits STAT3 phosphorylation and activities and exhibits potent growth-suppressive activity in human cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neoplasia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>39</sb:first-page>
                              <sb:last-page>50</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The small molecule, LLL12, inhibits STAT3 phosphorylation and induces apoptosis in medulloblastoma and glioblastoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>PLoS One</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e18820</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.N.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.D.</ce:given-name>
                                 <ce:surname>Shin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Yoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Han</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.M.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>69</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>193</sb:first-page>
                              <sb:last-page>202</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of Niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Terry</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of O-Alkylamino tethered Niclosamide derivatives as potent and orally bioavailable anticancer agents</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>180</sb:first-page>
                              <sb:last-page>185</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Flores</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of potent anticancer agent HJC0416, an orally bioavailable small molecule inhibitor of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>82</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>195</sb:first-page>
                              <sb:last-page>203</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Paladino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9623</sb:first-page>
                              <sb:last-page>9628</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hangoc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pollok</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Sandusky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Y.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.E.</ce:given-name>
                                 <ce:surname>Broxmeyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small-molecule inhibitors targeting the DNA-binding domain of STAT3 suppress tumor growth, metastasis and STAT3 target gene expression in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>783</sb:first-page>
                              <sb:last-page>792</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Groner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the Stat3beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.A.</ce:given-name>
                                 <ce:surname>Timofeeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gaponenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Lockett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Tarasov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Michejda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.O.</ce:given-name>
                                 <ce:surname>Perantoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.I.</ce:given-name>
                                 <ce:surname>Tarasova</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>799</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kotha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sekharam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cilenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khaled</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Zervos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Carter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>621</sb:first-page>
                              <sb:last-page>629</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Natarajan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Bright</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>168</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6506</sb:first-page>
                              <sb:last-page>6513</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Bharti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Donato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.B.</ce:given-name>
                                 <ce:surname>Aggarwal</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Curcumin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>171</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3863</sb:first-page>
                              <sb:last-page>3871</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Saturnino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Palladino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Napoli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Sinicropi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Botta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Carcereri de Prati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Suzuki</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>60</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>112</sb:first-page>
                              <sb:last-page>119</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Pallandre</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Borg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Rognan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Boibessot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Luzet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yesylevskyy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ramseyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pudlo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>163</sb:first-page>
                              <sb:last-page>174</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Ji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Mao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Qiao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel 2-carbonylbenzo[b]thiophene 1, 1-dioxide derivatives as potent inhibitors of STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1010</sb:first-page>
                              <sb:last-page>1014</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.B.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.D.</ce:given-name>
                                 <ce:surname>Geng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Kong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Calyxin Y induces hydrogen peroxide-dependent autophagy and apoptosis via JNK activation in human non-small cell lung cancer NCI-H460 cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>340</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>51</sb:first-page>
                              <sb:last-page>62</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>